Expression profiling by high-throughput sequencing reveals GADD45, SMAD7, EGR-1 and HOXA3 activation in Myostatin (MSTN) and GDF11 treated myoblasts
Braun P, Alawi M, Saygi C, Pantel K, Wagers A
GENET MOL BIOL. 2024;47(2):e20230304.

Relationship of Ki-67 index in biopsies of metastatic breast cancer tissue and circulating tumor cells (CTCs) at the time of biopsy collection
Deutsch T, Fischer C, Riedel F, Haßdenteufel K, Michel L, Sütterlin M, Riethdorf S, Pantel K, Wallwiener M, Schneeweiss A, Stefanovic S
ARCH GYNECOL OBSTET. 2024;309(1):235-248.

Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial
Fehm T, Mueller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Mueller L, Wimberger P, Ruckhaeberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W
CLIN CHEM. 2024;70(1):307-318.

Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma
Geidel G, Parnian N, Meß C, Schlepper N, Rünger A, Heidrich I, Hansen I, Smit D, Menz A, Pantel K, Schneider S, Kött J, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(10):2017-2023.

Liquid Biopsy – Ein neues diagnostisches Konzept in der Onkologie
Heidrich I, Roeper C, Rautmann C, Pantel K, Smit D
LARYNGO RHINO OTOL. 2024;103(1):40-46.

High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy
Kött J, Hoehne I, Heidrich I, Zimmermann N, Reese K, Zell T, Geidel G, Rünger A, Schneider S, Pantel K, Smit D, Gebhardt C
CANCERS. 2024;16(9):.

C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma
Kött J, Zimmermann N, Zell T, Heidrich I, Geidel G, Rünger A, Smit D, Merkle M, Parnian N, Hansen I, Hoehne I, Abeck F, Torster L, Weichenthal M, Pantel K, Schneider S, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(8):1575–1587.

KRAS and GNAS mutations in cell-free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms-an observational pilot study
Nitschke C, Tölle M, Walter P, Meißner K, Goetz M, Kropidlowski J, Berger A, Izbicki J, Nickel F, Hackert T, Pantel K, Wikman H, Uzunoglu F
MOL ONCOL. 2024 [Epub ahead of print].

EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma
Piper A, Penney C, Holliday J, Tincknell G, Ma Y, Napaki S, Pantel K, Brungs D, Ranson M
INT J MOL SCI. 2024;25(10):.

Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary
Pouyiourou M, Bochtler T, Coith C, Wikman H, Kraft B, Hielscher T, Stenzinger A, Riethdorf S, Pantel K, Krämer A
CLIN CHEM. 2024;70(1):297-306.

Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review
Reese K, Pantel K, Smit D
J EXP CLIN CANC RES. 2024;43(1):.

Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells
Rieckmann L, Spohn M, Ruff L, Agorku D, Becker L, Borchers A, Krause J, O'Reilly R, Hille J, Velthaus-Rusik J, Beumer N, Günther A, Willnow L, Imbusch C, Iglauer P, Simon R, Franzenburg S, Winter H, Thomas M, Bokemeyer C, Gagliani N, Krebs C, Sprick M, Hardt O, Riethdorf S, Trumpp A, Stoecklein N, Peine S, Rosenstiel P, Pantel K, Loges S, Janning M
MOL CANCER. 2024;23(1):93.

Circulating Tumor Cells and Thromboembolic Events in Patients with Glioblastoma
Rolling C, Mohme M, Bokemeyer C, Westphal M, Riethdorf S, Lamszus K, Pantel K, Klingler F, Langer F
HAMOSTASEOLOGIE. 2024 [Epub ahead of print].

HERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis
Schneegans S, Löptien J, Mojzisch A, Loreth D, Kretz O, Raschdorf C, Hanssen A, Gocke A, Siebels B, Gunasekaran K, Ding Y, Oliveira-Ferrer L, Brylka L, Schinke T, Schlüter H, Paatero I, Voß H, Werner S, Pantel K, Wikman H
J EXP CLIN CANC RES. 2024;43(1):110.

Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma
Sementsov M, Ott L, Kött J, Sartori A, Lusque A, Degenhardt S, Segier B, Heidrich I, Volkmer B, Greinert R, Mohr P, Simon R, Stadler J, Irwin D, Koch C, Andreas A, Deitert B, Thewes V, Trumpp A, Schneeweiss A, Belloum Y, Peine S, Wikman H, Riethdorf S, Schneider S, Gebhardt C, Pantel K, Keller L
EMBO MOL MED. 2024;16(7):1560-1578.

Analysis of the Plasticity of Circulating Tumor Cells Reveals Differentially Regulated Kinases During the Suspension-to-Adherent Transition
Smit D, Hoffer K, Bettin B, Kriegs M, Cayrefourcq L, Schumacher U, Pantel K, Alix-Panabières C, Jücker M
CANCER MED-US. 2024;13(20):e70339.

Circulating tumor cells as liquid biopsy markers in cancer patients
Smit D, Pantel K
MOL ASPECTS MED. 2024;96:101258.

Clinical applications of circulating tumor cells in patients with solid tumors
Smit D, Schneegans-Murano S, Pantel K
CLIN EXP METASTAS. 2024;41(4):403-411.

Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group
Wyatt A, Litière S, Bidard F, Cabel L, Dyrskjøt L, Karlovich C, Pantel K, Petrie J, Philip R, Andrews H, Vellanki P, Tolmeijer S, Villalobos Alberu X, Alfano C, Bogaerts J, Calvo E, Chen A, Toledo R, de Vries E, Seymour L, Laurie S, Garralda E
CLIN CANCER RES. 2024 [Epub ahead of print].

Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients
Abdo M, Belloum Y, Heigener D, Welker L, von Weihe S, Schmidt M, Heuer-Olewinski N, Watermann I, Szewczyk M, Kropidlowski J, Pereira-Veiga T, Elmas H, Perner S, Steurer S, Wikman H, Pantel K, Reck M
MOL ONCOL. 2023;17(5):737-746.

Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1
Bartkowiak K, Mossahebi Mohammadi P, Gärtner S, Kwiatkowski M, Andreas A, Geffken M, Peine S, Verpoort K, Scholz U, Deutsch T, Michel L, Schneeweiss A, Thewes V, Trumpp A, Müller V, Riethdorf S, Schlüter H, Pantel K
J PROTEOME RES. 2023;22(4):1213-1230.

Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model
Böckelmann L, Freytag V, Ahlers A, Maar H, Gosau T, Baranowsky A, Schmitz R, Pantel K, Schumacher U, Haider M, Lange T
BONE. 2023;171:116741.

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
Cieślikowski W, Milecki P, Świerczewska M, Ida A, Kasperczak M, Jankowiak A, Nowicki M, Pantel K, Alix-Panabières C, Zabel M, Antczak A, Budna-Tukan J
J PERS MED. 2023;13(4):.

PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy
Derlin T, Riethdorf S, Schumacher U, Lafos M, Peine S, Coith C, Ross T, Pantel K, Bengel F
PROSTATE. 2023;83(11):1076-1088.

Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value
Franken A, Kraemer A, Sicking A, Watolla M, Rivandi M, Yang L, Warfsmann J, Polzer B, Friedl T, Meier-Stiegen F, Stoecklein N, Dayan D, Riethdorf S, Mueller V, Pantel K, Koch A, Hartkopf A, Krawczyk N, Ruckhaeberle E, Niederacher D, Fehm T, Neubauer H
BRIT J CANCER. 2023;128(9):1742-1752.

Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22
Giannou A, Kempski J, Shiri A, Lücke J, Zhang T, Zhao L, Zazara D, Cortesi F, Riecken K, Amezcua Vesely M, Low J, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens K, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, Bedke T, Brockmann L, Starzonek S, Lange T, Koch C, Riethdorf S, Pelczar P, Böttcher M, Sabihi M, Huber F, Reeh M, Grass J, Wahib R, Seese H, Stüben B, Fard-Aghaie M, Duprée A, Scognamiglio P, Plitzko G, Meiners J, Soukou S, Wittek A, Manthey C, Maroulis I, Arck P, Perez D, Gao B, Zarogiannis S, Strowig T, Pasqualini R, Arap W, Gosálvez J, Kobold S, Prinz I, Guse A, Tachezy M, Ghadban T, Heumann A, Li J, Melling N, Mann O, Izbicki J, Pantel K, Schumacher U, Lohse A, Flavell R, Gagliani N, Huber S
IMMUNITY. 2023;56(1):125-142.e12.

Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors
Heidrich I, Deitert B, Werner S, Pantel K
CANCER METAST REV. 2023;42(1):161-182.

Liquid Biopsy  – Ein neues diagnostisches Konzept in der Onkologie
Heidrich I, Roeper C, Rautmann C, Pantel K, Smit D
DEUT MED WOCHENSCHR. 2023;148(10):597-604.

Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy
Hohmann N, Sprick M, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, Stenzinger A, Steindorf K, Delorme S, Schlemmer H, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli W, Trumpp A, Springfeld C
CTS-CLIN TRANSL SCI. 2023;16(12):2483-2493.

Label Efficient Classification in Liquid Biopsy Data by Self-supervision
Husseini H, Nielsen M, Pantel K, Wikman H, Riethdorf S, Werner R
2023. Bildverarbeitung für die Medizin 2023. Deserno T, Handels H, Maier A, Maier-Hein K, Palm C, Tolxdorff T (eds.). 1. ed. Springer Vieweg, 261-266.

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
Kocheise L, Schoenlein M, Behrends B, Joerg V, Casar C, Fründt T, Renné T, Heumann A, Li J, Huber S, Lohse A, Pantel K, Riethdorf S, Wege H, Schulze K, von Felden J
SCI REP-UK. 2023;13(1):20827.

Circulating tumour cells for early detection of clinically relevant cancer
Lawrence R, Watters M, Davies C, Pantel K, Lu Y
NAT REV CLIN ONCOL. 2023;20(7):487-500.

Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
Leest P, Janning M, Rifaela N, Azpurua M, Kropidlowski J, Loges S, Lozano N, Sartori A, Irwin D, Lamy P, Hiltermann T, Groen H, Pantel K, Kempen L, Wikman H, Schuuring E
INT J MOL SCI. 2023;24(17):.

Five plus three for the pancreas
Löhr J, Pantel K
CLIN CANCER RES. 2023;29(8):1387-1389.

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Walter P, Badbaran A, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Bardenhagen J, Stern L, Tintelnot J, Schönlein M, Sinn M, van der Leest P, Simon R, Heumann A, Izbicki J, Pantel K, Wikman H, Uzunoglu F
CLIN CHEM. 2023;69(3):295-307.

First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
Paschold L, Stein A, Thiele B, Tintelnot J, Henkes S, Coith C, Schultheiß C, Pantel K, Riethdorf S, Binder M
J IMMUNOTHER CANCER. 2023;11(6):.

RNF40 epigenetically modulates glycolysis to support the aggressiveness of basal-like breast cancer
Prokakis E, Jansari S, Boshnakovska A, Wiese M, Kusch K, Kramm C, Dullin C, Rehling P, Glatzel M, Pantel K, Wikman H, Johnsen S, Gallwas J, Wegwitz F
CELL DEATH DIS. 2023;14(9):641.

Zirkulierende Tumorzellen
Reimers N, Pantel K
2023. Kompendium Internistische Onkologie. Schmoll H (eds.). 5. ed. Berlin, Heidelberg: Springer, 1-7.

„Liquid biopsy“ – schon reif für Therapieentscheidungen?
Roeper C, Hoehne I, Schlepper N, Koch C, Pantel K, Smit D
best practice onkologie. 2023;18(5):194 - 202.

Experimental in vitro, ex vivo and in vivo models in prostate cancer research
Sailer V, von Amsberg G, Duensing S, Kirfel J, Lieb V, Metzger E, Offermann A, Pantel K, Schuele R, Taubert H, Wach S, Perner S, Werner S, Aigner A
NAT REV UROL. 2023;20(3):158-178.

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
Stadler J, Keller L, Mess C, Bauer A, Koett J, Geidel G, Heidrich I, Vidal-Y-Sy S, Andreas A, Stramaglia C, Sementsov M, Haberstroh W, Deitert B, Hoehne I, Reschke R, Haalck T, Pantel K, Gebhardt C, Schneider S
J IMMUNOTHER CANCER. 2023;11(5):.

Preclinical models to study patient-derived circulating tumor cells and metastasis
Suvilesh K, Manjunath Y, Pantel K, Kaifi J
TRENDS CANCER. 2023;9(4):355-371.

A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer
Thomsen L, Honoré A, Reisæter L, Almås B, Børretzen A, Helle S, Førde K, Kristoffersen E, Kaada S, Melve G, Haslerud T, Biermann M, Bigalke I, Kvalheim G, Azeem W, Olsen J, Gabriel B, Knappskog S, Halvorsen O, Akslen L, Bahn D, Pantel K, Riethdorf S, Ragde H, Gjertsen B, Øyan A, Kalland K, Beisland C
CANCER IMMUNOL IMMUN. 2023;72(7):2357-2373.

Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients
Tzschaschel M, Friedl T, Schochter F, Schütze S, Polasik A, Fehm T, Pantel K, Schindlbeck C, Schneeweiss A, Schreier J, Tesch H, Lorenz R, Aivazova-Fuchs V, Häberle L, Fasching P, Janni W, Rack B, Fink V
CLIN BREAST CANCER. 2023;23(6):e345-e353.

Liquid Biopsy to Catch the Epigenetic Changes in Endometrial Cancer
Alix-Panabières C, Pantel K
CLIN CHEM. 2022;68(6):745-747.

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma
Ammann N, Schwietzer Y, Mess C, Stadler J, Geidel G, Kött J, Pantel K, Schneider S, Utikal J, Bauer A, Gebhardt C
CANCERS. 2022;14(22):.

Circulating Cellular Communication Network Factor 1 Protein as a Sensitive Liquid Biopsy Marker for Early Detection of Breast Cancer
Bartkowiak K, Heidrich I, Kwiatkowski M, Banys-Paluchowski M, Andreas A, Wurlitzer M, Geffken M, Voß H, Zeller T, Blankenberg S, Peine S, Joosse S, Müller V, Schlüter H, Oliveira-Ferrer L, Pantel K
CLIN CHEM. 2022;68(2):344-353.

Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities
Bauer A, Gorzelanny C, Gebhardt C, Pantel K, Schneider S
CANCER TREAT REV. 2022;102:.

Expression Patterns and Corepressor Function of Retinoic Acid-induced 2 in Prostate Cancer
Besler K, Węglarz A, Keller L, von Amsberg G, Bednarz-Knoll N, Offermann A, Stoupiec S, Eltze E, Semjonow A, Boettcher L, Schneegans S, Perner S, Hauch S, Todenhöfer T, Peine S, Pantel K, Wikman H, Werner S
CLIN CHEM. 2022;68(7):973-983.

Spine Metastases in Immunocompromised Mice after Intracardiac Injection of MDA-MB-231-SCP2 Breast Cancer Cells
Brylka L, Jähn-Rickert K, Baranowsky A, Neven M, Horn M, Yorgan T, Wikman H, Werner S, Lübke A, Amling M, Busse B, Pantel K, Schinke T
CANCERS. 2022;14(3):.

With one eye on the future
Caldas C, Rescigno M, Turajlic S, Madabhushi A, Zhang Z, Lito P, Brown C, Pantel K, Haanen J, Duma N
CANCER CELL. 2022;40(3):221-225.

Possible tumour cell reimplantation during curative endoscopic therapy of superficial Barrett's carcinoma
Ehlken H, Schmitz R, Riethdorf S, Riethdorf L, Krause J, Karstens K, Schrader J, Viol F, Giannou A, Sterlacci W, Vieth M, Clauditz T, Kähler C, Mann O, Izbicki J, Huber S, Pantel K, Rösch T
GUT. 2022;71(2):277-286.

Regulation of bone homeostasis by MERTK and TYRO3
Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu T, Beitzen-Heineke A, Vargas-Delgado M, Pantel K, Bokemeyer C, Bhamidipati S, Darwish I, Masuda E, Burstyn-Cohen T, Alberto E, Ghosh S, Rothlin C, Hesse E, Taipaleenmäki H, Ben Batalla I, Loges S
NAT COMMUN. 2022;13(1):.

Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade
Eslami-S Z, Cortés-Hernández L, Thomas F, Pantel K, Alix-Panabières C
BRIT J CANCER. 2022;127(5):800-810.

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
Fründt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S, Pantel K, Huber S, Lohse A, Wege H, Schulze K
FRONT ONCOL. 2022;12:.

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma
Geidel G, Heidrich I, Kött J, Schneider S, Pantel K, Gebhardt C
NPJ PRECIS ONCOL. 2022;6(1):.

Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation
Gerratana L, Pierga J, Reuben J, Davis A, Wehbe F, Dirix L, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Bonotto M, Fernandez de Lascoiti A, De Mattos-Arruda L, Ignatiadis M, Sandri M, Generali D, De Angelis C, Dawson S, Janni W, Carañana V, Riethdorf S, Solomayer E, Puglisi F, Giuliano M, Pantel K, Bidard F, Cristofanilli M
ONCOLOGIST. 2022;27(7):e561-e570.

Tumor-Stroma Interaction in PDAC as a New Approach for Liquid Biopsy and its Potential Clinical Implications
Götze J, Nitschke C, Uzunoglu F, Pantel K, Sinn M, Wikman H
FRONT CELL DEV BIOL. 2022;10:.

Liquid biopsy: blood-based analyses of circulating cell-free DNA in xenografts
Heidrich I, Pantel K
EMBO MOL MED. 2022;14(8):.

Clinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions
Herbst J, Pantel K, Effenberger K, Wikman H
BRIT J CANCER. 2022;127(8):1403-1410.

Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer
Joosse S, Pantel K
CANCER RES. 2022;82(12):2213-2215.

Detection of Hypomethylation in Long-ctDNA
Joosse S, Pantel K
CLIN CHEM. 2022;68(9):1115-1117.

Tumor cell E-selectin ligands determine partialefficacy of bortezomib on spontaneous lung metastasis formation of solid human tumors in vivo
Lange T, Valentiner U, Wicklein D, Maar H, Labitzky V, Ahlers A, Starzonek S, Genduso S, Staffeldt L, Pahlow C, Dück A, Stürken C, Baranowsky A, Bauer A, Bulk E, Schwab A, Riecken K, Börnchen C, Kiefmann R, Abraham V, DeLisser H, Gemoll T, Habermann J, Block A, Pantel K, Schumacher U
MOL THER. 2022;30(4):1536-1552.

Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients
Leffers M, Herbst J, Kropidlowski J, Prieske K, Bohnen A, Peine S, Jaeger A, Prieske K, Goy Y, Schmalfeldt B, Pantel K, Wölber L, Effenberger K, Wikman H
CANCERS. 2022;14(16):.

Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels
Leong S, Naxerova K, Keller L, Pantel K, Witte M
CLIN EXP METASTAS. 2022;39(1):159-179.

Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Non-Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules
Manjunath Y, Suvilesh K, Mitchem J, Avella Patino D, Kimchi E, Staveley-O'Carroll K, Pantel K, Yi H, Li G, Harris P, Chaudhuri A, Kaifi J
JCO PRECIS ONCOL. 2022;6:.

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Merkens L, Sailer V, Lessel D, Janzen E, Greimeier S, Kirfel J, Perner S, Pantel K, Werner S, von Amsberg G
J EXP CLIN CANC RES. 2022;41(1):.

Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker
Ningsi R, Elazezy M, Stegat L, Laakmann E, Peine S, Riethdorf S, Müller V, Pantel K, Joosse S
CANCERS. 2022;14(11):.

Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma
Nitschke C, Markmann B, Konczalla L, Kropidlowski J, Pereira-Veiga T, Scognamiglio P, Schönrock M, Sinn M, Tölle M, Izbicki J, Pantel K, Uzunoglu F, Wikman H
BIOMEDICINES. 2022;10(11):.

Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma Patients
Nitschke C, Markmann B, Tölle M, Kropidlowski J, Belloum Y, Goetz M, Schlüter H, Kwiatkowski M, Sinn M, Izbicki J, Pantel K, Güngör C, Uzunoglu F, Wikman H
CANCERS. 2022;14(18):.

Metastatic Breast Cancer Recurrence after Bone Fractures
Obi N, Werner S, Thelen F, Becher H, Pantel K
CANCERS. 2022;14(3):.

Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation
Pantel K, Alix-Panabières C
J IMMUNOTHER CANCER. 2022;10(12):.

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Pascual J, Attard G, Bidard F, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker J, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho J, Tie J, Seoane J, Tarazona N, Yoshino T, Turner N
ANN ONCOL. 2022;33(8):750-768.

Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance
Pereira-Veiga T, Schneegans S, Pantel K, Wikman H
CELL REP. 2022;40(9):.

Characterization of immunologically detectable T-cell sensitization, Immunohistochemical detection of pro-inflammatory cytokines, and clinical parameters of patients after allogeneic intraoral bone grafting procedures: a prospective randomized controlled clinical trial in humans
Solakoglu Ö, Götz W, von Baehr V, Heydecke G, Pantel K, Schwarzenbach H
BMC ORAL HEALTH. 2022;22(1):.

Current and future clinical applications of ctDNA in immuno-oncology
Stadler J, Belloum Y, Deitert B, Sementsov M, Heidrich I, Gebhardt C, Keller L, Pantel K
CANCER RES. 2022;82(3):349-358.

Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses
Suvilesh K, Nussbaum Y, Radhakrishnan V, Manjunath Y, Avella D, Staveley-O'Carroll K, Kimchi E, Chaudhuri A, Shyu C, Li G, Pantel K, Warren W, Mitchem J, Kaifi J
MOL CANCER. 2022;21(1):.

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
Volmer L, Koch A, Matovina S, Dannehl D, Weiss M, Welker G, Hahn M, Engler T, Wallwiener M, Walter C, Oberlechner E, Brucker S, Pantel K, Hartkopf A
CANCERS. 2022;14(3):.

Heparan sulfate dependent binding of plasmatic von Willebrand factor to blood circulating melanoma cells attenuates metastasis
Wang Y, Liu X, Obser T, Bauer A, Heyes M, Starzonek S, Zulal M, Opitz K, Ott L, Riethdorf S, Lange T, Pantel K, Bendas G, Schneider S, Kusche-Gullberg M, Gorzelanny C
MATRIX BIOL. 2022;111:76-94.

Clinical management and biology of tumor dormancy in breast cancer
Werner S, Heidrich I, Pantel K
SEMIN CANCER BIOL. 2022;78:49-62.

Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations
Westphal M, Pantel K, Ricklefs F, Maire C, Riethdorf S, Mohme M, Wikman H, Lamszus K
NEURO-ONCOL ADV. 2022;4(Suppl 2):ii45-ii52.

Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
Woo H, Kim S, Kang H, Lee S, Lee S, Kim J, Gurel O, Kim S, Roh H, Lee J, Park Y, Shin H, Shin Y, Lee S, Oh S, Kim Y, Chae J, Lee S, Hong M, Cho B, Lee E, Pantel K, Kim H, Kim M
THERANOSTICS. 2022;12(8):3676-3689.

Evaluation of the Hamburg-Glasgow Classification in Pancreatic Cancer: Preoperative Staging by Combining Disseminated Tumor Load and Systemic Inflammation
Abdalla T, Almanfalouti V, Effenberger K, Uzunoglu F, Ghadban T, Dupreé A, Izbicki J, Pantel K, Reeh M
CANCERS. 2021;13(23):.

Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer
Abdalla T, Meiners J, Riethdorf S, König A, Melling N, Gorges T, Karstens K, Izbicki J, Pantel K, Reeh M
PLOS ONE. 2021;16(6):e0252897.

Blood-based detection of lung cancer using cysteine-rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study
Ac Kar L, Casjens S, Andreas A, Raiko I, Brüning T, Geffken M, Peine S, Kollmeier J, Johnen G, Bartkowiak K, Weber D, Pantel K
MOL ONCOL. 2021;15(11):2877-2890.

Liquid Biopsy: From Discovery to Clinical Application
Alix-Panabières C, Pantel K
CANCER DISCOV. 2021;11(4):858-873.

Liquid biopsy: from discovery to clinical implementation
Alix-Panabières C, Pantel K
MOL ONCOL. 2021;15(6):1617-1621.

ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing
Asperger H, Cieslik J, Alberter B, Köstler C, Polzer B, Müller V, Pantel K, Riethdorf S, Koch A, Hartkopf A, Wiesmüller L, Janni W, Schochter F, Franken A, Niederacher D, Fehm T, Neubauer H
TRANSL ONCOL. 2021;14(8):101132.

Sensitive Blood-Based Detection of Asbestos-Associated Diseases Using Cysteine-Rich Angiogenic Inducer 61 as Circulating Protein Biomarker
Bartkowiak K, Casjens S, Andreas A, Ačkar L, Joosse S, Raiko I, Brüning T, Geffken M, Peine S, Johnen G, Weber D, Pantel K
CLIN CHEM. 2021;67(2):363-373.

Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer Cells
Bartkowiak K, Heidrich I, Kwiatkowski M, Gorges T, Andreas A, Geffken M, Verpoort K, Müller V, Schlüter H, Pantel K
CANCERS. 2021;13(3):.

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms
Beitzen-Heineke A, Berenbrok N, Waizenegger J, Päsler S, Gensch V, Udonta F, Vargas-Delgado M, Engelmann J, Hoffmann F, Schafhausen P, von Amsberg G, Riecken K, Beumer N, Imbusch C, Lorens J, Fischer T, Pantel K, Bokemeyer C, Ben Batalla I, Loges S
HEMASPHERE. 2021;5(9):.

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B, Pantel K, Joosse S
MOL ONCOL. 2021;15(12):3615-3625.

Emerging Insights into Keratin 16 Expression during Metastatic Progression of Breast Cancer
Elazezy M, Schwentesius S, Stegat L, Wikman H, Werner S, Mansour W, Failla A, Peine S, Müller V, Thiery J, Ebrahimi Warkiani M, Pantel K, Joosse S
CANCERS. 2021;13(15):.

Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
Hartkopf A, Brucker S, Taran F, Harbeck N, von Au A, Naume B, Pierga J, Hoffmann O, Beckmann M, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, Schuetz F, Borgen E, Ta M, Bittner A, Fasching P, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard F, Kasimir-Bauer S, Schoenfisch B, Kurt A, Wallwiener M, Gebauer G, Klein C, Wallwiener D, Janni W, Pantel K
EUR J CANCER. 2021;154:128-137.

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer
Heidrich I, Abdalla T, Reeh M, Pantel K
CANCERS. 2021;13(18):.

Liquid biopsies: Potential and challenges
Heidrich I, Ačkar L, Mossahebi Mohammadi P, Pantel K
INT J CANCER. 2021;148(3):528-545.

Novel approaches to target the microenvironment of bone metastasis
Hofbauer L, Bozec A, Rauner M, Jakob F, Perner S, Pantel K
NAT REV CLIN ONCOL. 2021;18(8):488-505.

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Keller L, Belloum Y, Wikman H, Pantel K
BRIT J CANCER. 2021;124(2):345-358.

Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence
Knipper S, Riethdorf S, Werner S, Tilki D, Graefen M, Pantel K, Maurer T
EUR UROL OPEN SCI. 2021;34:55-58.

CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis
Loreth D, Schuette M, Zinke J, Mohme M, Piffko A, Schneegans S, Stadler J, Janning M, Loges S, Joosse S, Lamszus K, Westphal M, Müller V, Glatzel M, Matschke J, Gebhardt C, Schneider S, Belczacka I, Volkmer B, Greinert R, Yaspo M, Harter P, Pantel K, Wikman H
INT J MOL SCI. 2021;22(13):.

Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification
Maire C, Fuh M, Kaulich K, Fita K, Stevic I, Heiland D, Welsh J, Jones J, Görgens A, Ricklefs T, Dührsen L, Sauvigny T, Joosse S, Reifenberger G, Pantel K, Glatzel M, Miklosi A, Felce J, Caselli M, Pereno V, Reimer R, Schlüter H, Westphal M, Schüller U, Lamszus K, Ricklefs F
NEURO-ONCOLOGY. 2021;23(7):1087-1099.

Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial
Mandel P, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T
EUR UROL FOCUS. 2021;7(1):55-62.

Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments
Mieczkowska I, Pantelaiou-Prokaki G, Prokakis E, Schmidt G, Müller-Kirschbaum L, Werner M, Sen M, Velychko T, Jannasch K, Dullin C, Napp J, Pantel K, Wikman H, Wiese M, Kramm C, Alves F, Wegwitz F
CELL DEATH DIS. 2021;12(12):.

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Müller V, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T
ESMO OPEN. 2021;6(6):.

Detection of Circulating Tumor Cells (CTCs) in Patients with Testicular Germ Cell Tumors
Nastały P, Honecker F, Pantel K, Riethdorf S
Methods Mol Biol. 2021;2195:245-261.

Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID
Neves R, Ammerlaan W, Andree K, Bender S, Cayrefourcq L, Driemel C, Koch C, Luetke-Eversloh M, Oulhen M, Rossi E, Alix-Panabières C, Betsou F, Farace F, Riethdorf S, Schlange T, Wikman H, Zamarchi R, Pantel K, Terstappen L, Stoecklein N
CLIN CHEM. 2021;67(4):631-641.

Analysis of tripartite motif (TRIM) family gene expression in prostate cancer bone metastases
Offermann A, Kang D, Watermann C, Weingart A, Hupe M, Saraji A, Stegmann-Frehse J, Kruper R, Schüle R, Pantel K, Taubert H, Duensing S, Culig Z, Aigner A, Klapper W, Jonigk D, Philipp Kühnel M, Merseburger A, Kirfel J, Sailer V, Perner S
CARCINOGENESIS. 2021;42(12):1475-1484.

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions
Pantano F, Croset M, Driouch K, Bednarz-Knoll N, Iuliani M, Ribelli G, Bonnelye E, Wikman H, Geraci S, Bonin F, Simonetti S, Vincenzi B, Hong S, Sousa S, Pantel K, Tonini G, Santini D, Clézardin P
ONCOGENE. 2021;40(7):1284-1299.

Liquid Biopsy: Blood-Based Analyses of ctDNA and CTCs
Pantel K
CLIN CHEM. 2021;67(11):1437-1439.

High Serum Levels of Wnt Signaling Antagonist Dickkopf-Related Protein 1 Are Associated with Impaired Overall Survival and Recurrence in Esophageal Cancer Patients
Ramirez J, Smit D, Viol F, Schrader J, Ghadban T, Pantel K, Izbicki J, Reeh M
CANCERS. 2021;13(19):.

Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain
Robador J, Feinauer M, Schneider S, Mayer F, Gorzelanny C, Sacharow A, Liu X, Berghoff A, Brehm M, Hirsch D, Stadler J, Vidal-Y-Si S, Wladykowski E, Asong M, Nowak K, Seiz-Rosenhagen M, Umansky V, Mess C, Pantel K, Winkler F, Bauer A
NEURO-ONCOL ADV. 2021;3(1):.

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer
Roßwag S, Cotarelo C, Pantel K, Riethdorf S, Sleeman J, Schmidt M, Thaler S
CANCERS. 2021;13(8):.

Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy
Smit D, Pantel K, Jücker M
BIOCHEM PHARMACOL. 2021;188:114589.

A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer
Strati A, Zavridou M, Kallergi G, Politaki E, Kuske A, Gorges T, Riethdorf S, Joosse S, Koch C, Bohnen A, Mueller V, Koutsodontis G, Kontopodis E, Poulakaki N, Psyrri A, Mavroudis D, Georgoulias V, Pantel K, Lianidou E
CLIN CHEM. 2021;67(10):1395-1405.

Circulating DNA and other biomarker for early diagnosis: Great potential, but challenges recognized
Babayan A, Reimers N, Pantel K
2020. World Cancer Report. Wild C, Weiderpass E, Stewart B (eds.). 1. ed. Lyon: World Health Organization, 550 -556.

In Vitro Modeling of Reoxygenation Effects on mRNA and Protein Levels in Hypoxic Tumor Cells upon Entry into the Bloodstream
Bartkowiak K, Koch C, Gärtner S, Andreas A, Gorges T, Pantel K
CELLS-BASEL. 2020;9(5):.

Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay
Belloum Y, Janning M, Mohme M, Simon R, Kropidlowski J, Sartori A, Irwin D, Westphal M, Lamszus K, Loges S, Riethdorf S, Pantel K, Wikman H
CELLS-BASEL. 2020;9(11):.

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
Bergmann S, Coym A, Ott L, Soave A, Rink M, Janning M, Stoupiec M, Coith C, Peine S, von Amsberg G, Pantel K, Riethdorf S
ONCOIMMUNOLOGY. 2020;9(1):.

HER2-targeted therapy influences CTC status in metastatic breast cancer
Deutsch T, Riethdorf S, Fremd C, Feisst M, Nees J, Fischer C, Hartkopf A, Pantel K, Trumpp A, Schütz F, Schneeweiss A, Wallwiener M
BREAST CANCER RES TR. 2020;182(1):127-136.

Rationale and Design of the Hamburg City Health Study
Jagodzinski A, Johansen C, Koch-Gromus U, Aarabi G, Adam G, Anders S, Augustin M, der Kellen R, Beikler T, Behrendt C, Betz C, Bokemeyer C, Borof K, Briken P, Busch C, Büchel C, Brassen S, Debus E, Eggers L, Fiehler J, Gallinat J, Gellißen S, Gerloff C, Girdauskas E, Gosau M, Graefen M, Härter M, Harth V, Heidemann C, Heydecke G, Huber T, Hussein Y, Kampf M, von dem Knesebeck O, Konnopka A, König H, Kromer R, Kubisch C, Kühn S, Loges S, Löwe B, Lund G, Meyer C, Nagel L, Nienhaus A, Pantel K, Petersen E, Püschel K, Reichenspurner H, Sauter G, Scherer M, Scherschel K, Schiffner U, Schnabel R, Schulz H, Smeets R, Sokalskis V, Spitzer M, Terschüren C, Thederan I, Thoma T, Thomalla G, Waschki B, Wegscheider K, Wenzel J, Wiese S, Zyriax B, Zeller T, Blankenberg S
EUR J EPIDEMIOL. 2020;35(2):169-181.

Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer
Joosse S, Beyer B, Gasch C, Nastały P, Kuske A, Isbarn H, Horst L, Hille C, Gorges T, Cayrefourcq L, Alix-Panabières C, Tennstedt P, Riethdorf S, Schlomm T, Pantel K
CLIN CHEM. 2020;66(1):161-168.

Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer
Karstens K, Ghadban T, Effenberger K, Sauter G, Pantel K, Izbicki J, Vashist Y, König A, Reeh M
CANCERS. 2020;12(3):588.

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Koch C, Kuske A, Joosse S, Yigit G, Sflomos G, Thaler S, Smit D, Werner S, Borgmann K, Gärtner S, Mossahebi Mohammadi P, Battista L, Cayrefourcq L, Altmüller J, Salinas-Riester G, Raithatha K, Zibat A, Goy Y, Ott L, Bartkowiak K, Tan T, Zhou Q, Speicher M, Müller V, Gorges T, Jücker M, Thiery J, Brisken C, Riethdorf S, Alix-Panabières C, Pantel K
EMBO MOL MED. 2020;12(9):.

Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows
Lampignano R, Neumann M, Weber S, Kloten V, Herdean A, Voss T, Groelz D, Babayan A, Tibbesma M, Schlumpberger M, Chemi F, Rothwell D, Wikman H, Galizzi J, Bergheim I, Russnes H, Mussolin B, Bonin S, Voigt C, Musa H, Pinzani P, Lianidou E, Brady G, Speicher M, Pantel K, Betsou F, Schuuring E, Kubista M, Ammerlaan W, Sprenger-Haussels M, Schlange T, Heitzer E
CLIN CHEM. 2020;66(1):149-160.

Author Correction: Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases
Le U, Bronsert P, Picardo F, Riethdorf S, Haager B, Rylski B, Czerny M, Beyersdorf F, Wiesemann S, Pantel K, Passlick B, Kaifi J, Schmid S
SCI REP-UK. 2020;10(1):7633.

Evaluation of Microfluidic Ceiling Designs for the Capture of Circulating Tumor Cells on a Microarray Platform
Liu H, Koch C, Haller A, Joosse S, Kumar R, Vellekoop M, Horst L, Keller L, Babayan A, Failla A, Jensen J, Peine S, Keplinger F, Fuchs H, Pantel K, Hirtz M
ADV BIOSYST. 2020;4(2):e1900162.

Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape
Mohme M, Maire C, Schliffke S, Joosse S, Alawi M, Matschke J, Schüller U, Dierlamm J, Martens T, Pantel K, Riethdorf S, Lamszus K, Westphal M
ACTA NEUROPATHOL COM. 2020;8(1):.

ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium
Münsterberg J, Loreth D, Brylka L, Werner S, Karbanova J, Gandrass M, Schneegans S, Besler K, Hamester F, Robador J, Bauer A, Werner Schneider S, Wrage M, Lamszus K, Matschke J, Vashist Y, Uzunoglu G, Steurer S, Horst A, Oliveira-Ferrer L, Glatzel M, Schinke T, Corbeil D, Pantel K, Maire C, Wikman H
NEURO-ONCOLOGY. 2020;22(7):955-966.

The Impact of Circulating Tumor Cells on Venous Thromboembolism and Cardiovascular Events in Bladder Cancer Patients Treated with Radical Cystectomy
Rink M, Riethdorf S, Yu H, Kölker M, Vetterlein M, Dahlem R, Fisch M, Pantel K, Soave A
J CLIN MED. 2020;9(11):.

Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients
Schneegans S, Lück L, Besler K, Bluhm L, Stadler J, Staub J, Greinert R, Volkmer B, Kubista M, Gebhardt C, Sartori A, Irwin D, Serkkola E, Af Hällström T, Lianidou E, Sprenger-Haussels M, Hussong M, Mohr P, Schneider S, Shaffer J, Pantel K, Wikman H
MOL ONCOL. 2020;14(5):1001-1015.

High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors
Smit D, Cayrefourcq L, Haider M, Hinz N, Pantel K, Alix-Panabières C, Jücker M
CELLS-BASEL. 2020;9(9):.

Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
Soave A, Kluwe L, Yu H, Rink M, Gild P, Vetterlein M, Marks P, Sauter G, Fisch M, Meyer C, Ludwig T, Dahlem R, Minner S, Pantel K, Steinbach B, Schwarzenbach H
SCI REP-UK. 2020;10(1):21562.

The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
Stefanovic S, Deutsch T, Riethdorf S, Fischer C, Hartkopf A, Sinn P, Feisst M, Pantel K, Golatta M, Brucker S, Sütterlin M, Schneeweiss A, Wallwiener M
INT J MOL SCI. 2020;21(6):.

Correction: Role of growth arrest-specific gene 6-mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Atanackovic D, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2020;34(9):2542.

Clinical Relevance of Circulating Tumor Cells in Esophageal Cancer Detected by a Combined MACS Enrichment Method
Woestemeier A, Harms-Effenberger K, Karstens K, Konczalla L, Ghadban T, Uzunoglu F, Izbicki J, Bockhorn M, Pantel K, Reeh M
CANCERS. 2020;12(3):718.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Banys-Paluchowski M, Witzel I, Aktas B, Fasching P, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer E, Fehm T, Müller V
SCI REP-UK. 2019;9(1):2318.

Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays
Budna-Tukan J, Świerczewska M, Mazel M, Cieślikowski W, Ida A, Jankowiak A, Antczak A, Nowicki M, Pantel K, Azria D, Zabel M, Alix-Panabières C
CANCERS. 2019;11(6):.

In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy
Chen S, Tauber G, Langsenlehner T, Schmölzer L, Pötscher M, Riethdorf S, Kuske A, Leitinger G, Kashofer K, Czyż Z, Polzer B, Pantel K, Sedlmayr P, Kroneis T, El-Heliebi A
CANCERS. 2019;11(7):.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
Cristofanilli M, Pierga J, Reuben J, Rademaker A, Davis A, Peeters D, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti A, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere S, Meier-Stiegen F, Sandri M, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti M, Diaz-Rubio E, Krell J, Dawson S, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer E, Zorzino L, Darrigues L, Reis-Filho J, Gerratana L, Michiels S, Bidard F, Pantel K
CRIT REV ONCOL HEMAT. 2019;134:39-45.

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients
Gorges K, Wiltfang L, Gorges T, Sartori A, Hildebrandt L, Keller L, Volkmer B, Peine S, Babayan A, Moll I, Schneider S, Twarock S, Mohr P, Fischer J, Pantel K
CANCERS. 2019;11(11):1685.

Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer
Hille C, Gorges T, Riethdorf S, Mazel M, Steuber T, Amsberg G, König F, Peine S, Alix-Panabières C, Pantel K
CELLS-BASEL. 2019;8(9):.

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S, Schatz S, Falk M, Berger L, Böttcher L, Päsler S, Gorges T, O'Flaherty L, Hille C, Joosse S, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S
CANCERS. 2019;11(6):.

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer
Jauch S, Riethdorf S, Sprick M, Schütz F, Schönfisch B, Brucker S, Deutsch T, Nees J, Saini M, Becker L, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A
BREAST CANCER RES TR. 2019;173(1):155-165.

Biology and clinical relevance of EpCAM
Keller L, Werner S, Pantel K
CELL STRESS. 2019;3(6):165-180.

Prospective Comparison of the Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of a Single Patient's Cohort With Esophageal Cancer
Konczalla L, Ghadban T, Effenberger K, Wöstemeier A, Riethdorf S, Uzunoglu F, Izbicki J, Pantel K, Bockhorn M, Reeh M
ANN SURG. 2019;273(2):299-305.

Liquid Biopsies
Lianidou E, Pantel K
GENE CHROMOSOME CANC. 2019;58(4):219-232.

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
Lindsay C, Blackhall F, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen H, Hiltermann T, Krebs M, Loges S, López-López R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria J, Farace F, Renehan A, Dive C, Besse B, Michiels S
EUR J CANCER. 2019;117:60-68.

ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer
Nastały P, Filipska M, Morrissey C, Eltze E, Semjonow A, Brandt B, Pantel K, Bednarz-Knoll N
TRANSL RES. 2019;203:49-56.

Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer
Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N
INT J CANCER. 2019;144(3):607-614.

Liquid biopsy and minimal residual disease - latest advances and implications for cure
Pantel K, Alix-Panabières C
NAT REV CLIN ONCOL. 2019;16(7):409-424.

Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility
Pantel K, Hille C, Scher H
CLIN CHEM. 2019;65(1):87-99.

Möglichkeiten und Grenzen von Liquid Biopsy
Pantel K, Reimers N
Osteoporose, Orthopädie &Rheuma aktuell. 2019;2019(4):.

Liquid biopsy: novel technologies and clinical applications
Reimers N, Pantel K
CLIN CHEM LAB MED. 2019;57(3):312-316.

Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours
Ricklefs F, Maire C, Reimer R, Dührsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, Pantel K, Krasemann S, Glatzel M, Heiland D, Flitsch J, Martens T, Schmidt N, Peine S, Breakefield X, Lawler S, Chiocca E, Fehse B, Giebel B, Görgens A, Westphal M, Lamszus K
J EXTRACELL VESICLES. 2019;8(1):1588555.

Clonality of circulating tumor cells in breast cancer brain metastasis patients
Riebensahm C, Joosse S, Mohme M, Hanssen A, Matschke J, Goy Y, Witzel I, Lamszus K, Kropidlowski J, Petersen C, Kolb-Kokocinski A, Sauer S, Borgmann K, Glatzel M, Müller V, Westphal M, Riethdorf S, Pantel K, Wikman H
BREAST CANCER RES. 2019;21(1):101.

Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma
Riethdorf S, Hildebrandt L, Heinzerling L, Heitzer E, Fischer N, Bergmann S, Mauermann O, Waldispühl-Geigl J, Coith C, Schön G, Peine S, Schuler G, Speicher M, Moll I, Pantel K
CLIN CHEM. 2019;65(3):462-472.

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients
Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, Lamszus K, Goy Y, Petersen C, Westphal M, Glatzel M, Riethdorf S, Pantel K, Wikman H
SCI REP-UK. 2019;9(1):7406.

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch J, Friedl T, Fasching P, Haeberle L, Fehm T, Schneeweiss A, Beckmann M, Pantel K, Mueller V, Rack B, Scholz C
JNCI-J NATL CANCER I. 2019;111(4):380-387.

11th International Symposium on Minimal Residual Cancer (ISMRC): 3-5 May 2018, Montpellier, France
Alix-Panabières C, Pantel K
CLIN EXP METASTAS. 2018;35(3):87-90.

Abstracts from the 11th International Symposium on Minimal Residual Disease, 3-5 May 2018, Montpellier, France
Alix-Panabières C, Pantel K
CLIN EXP METASTAS. 2018;35(3):167-217.

Clinical utility of circulating non-coding RNAs - an update
Anfossi S, Babayan A, Pantel K, Calin G
NAT REV CLIN ONCOL. 2018;15(9):541-563.

Advances in liquid biopsy approaches for early detection and monitoring of cancer
Babayan A, Pantel K
GENOME MED. 2018;10(1):21.

Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany
Bailey D, Pichler B, Gückel B, Antoch G, Barthel H, Bhujwalla Z, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren R, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen G, Krackhardt A, Law I, Morris J, Nikolaou K, Nuyts J, Ordonez A, Pantel K, Quick H, Riklund K, Sabri O, Sattler B, Troost E, Zaiss M, Zender L, Beyer T
MOL IMAGING BIOL. 2018;20(1):4-20.

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching P, Kasimir-Bauer S, Milde-Langosch K, Pantel K, Rack B, Riethdorf S, Solomayer E, Witzel I, Müller V
BMC CANCER. 2018;18(1):541.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Banys-Paluchowski M, Fehm T, Witzel I, Aktas B, Fasching P, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer E, Müller V
GEBURTSH FRAUENHEILK. 2018;78(11):1151.

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer
Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching P, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer E, Fehm T, Müller V
BREAST CANCER RES TR. 2018;172(1):93-104.

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment
Bauer E, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl T, Fasching P, Fehm T, Schneeweiss A, Beckmann M, Pantel K, Janni W, Rack B, Scholz C
BREAST CANCER RES TR. 2018;171(3):571-580.

Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy
Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner J, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S
CANCER RES. 2018;78(12):3220-3232.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
Berger L, Janning M, Velthaus J, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S
J THORAC ONCOL. 2018;13(12):e243-e246.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-Analysis: A Meta-analysis
Bidard F, Michiels S, Riethdorf S, Mueller V, Esserman L, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz J, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua M, Hall C, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran F, Cappelletti M, Ignatiadis M, Proudhon C, Wolf D, Bauldry J, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker S, Weber K, Reyal F, Amara D, Karhade M, Mathiesen R, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Pantel K
JNCI-J NATL CANCER I. 2018;110(6):560-567.

Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer
Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Burwinkel B
BREAST CANCER RES TR. 2018;169(1):69-82.

Target Cell Pre-enrichment and Whole Genome Amplification for Single Cell Downstream Characterization
Chen S, El-Heliebi A, Schmid J, Kashofer K, Czyż Z, Polzer B, Pantel K, Kroneis T, Sedlmayr P
JOVE-J VIS EXP. 2018;(135):e56394.

miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes
Croset M, Pantano F, Kan C, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier C, Bachelier R, Allioli N, Hong S, Bartkowiak K, Pantel K, Clézardin P
CANCER RES. 2018;78(18):5259-5273.

Improved risk stratification by circulating tumor cell counts in pancreatic cancer
Effenberger K, Schroeder C, Hanssen A, Wolter S, Eulenburg C, Tachezy M, Gebauer F, Izbicki J, Pantel K, Bockhorn M
CLIN CANCER RES. 2018;24(12):2844-2850.

In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells
El-Heliebi A, Hille C, Laxman N, Svedlund J, Haudum C, Ercan E, Kroneis T, Chen S, Smolle M, Rossmann C, Krzywkowski T, Ahlford A, Darai E, von Amsberg G, Alsdorf W, König F, Löhr M, de Kruijff I, Riethdorf S, Gorges T, Pantel K, Bauernhofer T, Nilsson M, Sedlmayr P
CLIN CHEM. 2018;64(3):536-546.

Hemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells
Follain G, Osmani N, Azevedo A, Allio G, Mercier L, Karreman M, Solecki G, Garcia Leòn M, Lefebvre O, Fekonja N, Hille C, Chabannes V, Dollé G, Metivet T, Hovsepian F, Prudhomme C, Pichot A, Paul N, Carapito R, Bahram S, Ruthensteiner B, Kemmling A, Siemonsen S, Schneider T, Fiehler J, Glatzel M, Winkler F, Schwab Y, Pantel K, Harlepp S, Goetz J
DEV CELL. 2018;45(1):33-52.e12.

Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases
Gerstenberger W, Wrage M, Kettunen E, Pantel K, Anttila S, Steurer S, Wikman H
ANAL CELL PATHOL. 2018;2018:8651790.

Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage
Gschwend J, Albers P, Bögemann M, Goebell P, Heidenreich A, Klier J, König F, Machtens S, Pantel K, Thomas C
UROLOGE. 2018;57(1):34-39.

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
Hanssen A, Riebensahm C, Mohme M, Joosse S, Velthaus J, Berger L, Bernreuther C, Glatzel M, Loges S, Lamszus K, Westphal M, Riethdorf S, Pantel K, Wikman H
CANCERS. 2018;10(12):E527.

Circulating tumour cells in prostate cancer
Hille C, Pantel K
NAT REV UROL. 2018;15(5):265-266.

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial
Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga J
ANN ONCOL. 2018;29(8):1777-1783.

Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients
Joosse S, Souche F, Babayan A, Gasch C, Kerkhoven R, Ramos J, Fabre J, Riethdorf S, König A, Wikman H, Alix-Panabières C, Pantel K
CLIN CHEM. 2018;64(10):1505-1512.

Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer
Lange T, Oh-Hohenhorst S, Joosse S, Pantel K, Hahn O, Gosau T, Dyshlovoy S, Wellbrock J, Feldhaus S, Maar H, Gehrcke R, Kluth M, Simon R, Schlomm T, Huland H, Schumacher U
SCI REP-UK. 2018;8:17535.

Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases
Le U, Bronsert P, Picardo F, Riethdorf S, Haager B, Rylski B, Czerny M, Beyersdorf F, Wiesemann S, Pantel K, Passlick B, Kaifi J, Schmid S
SCI REP-UK. 2018;8(1):8751.

Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients
Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, Kuske A, Gorges T, Joosse S, Kroneis T, Zabel M, Sedlmayr P, Alix-Panabières C, Pantel K, Lianidou E
CLIN CHEM. 2018;64(2):297-306.

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients
Ni Q, Stevic I, Pan C, Müller V, Oliviera-Ferrer L, Pantel K, Schwarzenbach H
SCI REP-UK. 2018;8:12974.

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
Pan C, Stevic I, Müller V, Ni Q, Ferrer L, Pantel K, Schwarzenbach H
MOL ONCOL. 2018;12(11):1935-1948.

Disseminated breast tumour cells: biological and clinical meaning: biological and clinical meaning
Pantel K, Hayes D
NAT REV CLIN ONCOL. 2018;15(3):129-131.

Profiling circulating tumour cells and other biomarkers of invasive cancers
Poudineh M, Sargent E, Pantel K, Kelley S
NAT BIOMED ENG. 2018;2(2):72-84.

Aktuelles zur Liquid Biopsy
Reimers N, Hille C, Pantel K
InFo Onkologie. 2018;21(Suppl. 1):24-29.

Clinical applications of the CellSearch platform in cancer patients
Riethdorf S, O'Flaherty L, Hille C, Pantel K
ADV DRUG DELIVER REV. 2018;125:102-121.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer
Schiewek J, Schumacher U, Lange T, Joosse S, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S
J CANCER RES CLIN. 2018;144(11):2195-2205.

Inverse Perfusion Requirements of Supra- and Infratentorial Brain Metastases Formation
Schneider T, Kemmling A, Schroeder J, Pantel K, Glatzel M, Schoen G, Mohme M, Fiehler J, Gellißen S
FRONT NEUROL. 2018;9:391.

Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study
Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, Schneeweiss A, Müller V, Pantel K, Gade J, Lorenz R, Rezai M, Tesch H, Soeling U, Fehm T, Mahner S, Schindlbeck C, Lichtenegger W, Beckmann M, Fasching P, Janni W, Friedl T
ONCOL RES TREAT. 2018;41(3):93-98.

Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy."
Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M
UROL ONCOL-SEMIN ORI. 2018;36(7):347-348.

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes
Soler A, Cayrefourcq L, Mazard T, Babayan A, Lamy P, Assou S, Assenat E, Pantel K, Alix-Panabières C
SCI REP-UK. 2018;8(1):15931.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
Stevic I, Müller V, Weber K, Fasching P, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H
BMC MED. 2018;16(1):179.

Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer
Woestemeier A, Ghadban T, Riethdorf S, Harms-Effenberger K, Konczalla L, Uzunoglu F, Izbicki J, Pantel K, Bockhorn M, Reeh M
ANTICANCER RES. 2018;38(10):5665-5669.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S
HAEMATOLOGICA. 2018;103(6):939-948.

Epithelial-mesenchymal plasticity in circulating tumor cells
Alix-Panabières C, Mader S, Pantel K
J MOL MED. 2017;95(2):133-142.

Biological Labels: Here comes the spaser
Alix-Panabières C, Pantel K
NAT MATER. 2017;16(8):790-791.

Characterization of Single Circulating Tumor Cells
Alix-Panabières C, Pantel K
FEBS LETT. 2017;591(15):2241 - 2250.

Detection of Circulating Plasma Cells in Multiple Myeloma
Alix-Panabières C, Pantel K
CLIN CHEM. 2017;63(12):1797-1798.

Plasma microRNA signature is associated with risk stratification in prostate cancer patients
Al-Qatati A, Akrong C, Stevic I, Pantel K, Awe J, Saranchuk J, Drachenberg D, Mai S, Schwarzenbach H
INT J CANCER. 2017;141(6):1231-1239.

Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells
Babayan A, Alawi M, Gormley M, Müller V, Wikman H, McMullin R, Smirnov D, Li W, Geffken M, Pantel K, Joosse S
ONCOTARGET. 2017;8(34):56066-56080.

Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients
Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V
ANTICANCER RES. 2017;37(6):3117-3128.

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
Banys-Paluchowski M, Witzel I, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Müller V
SCI REP-UK. 2017;7(1):Art. 17307.

Liquid Biopsies, What We Do Not Know (Yet)
Bardelli A, Pantel K
CANCER CELL. 2017;31(2):172-179.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia
Ben Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus J, Rankin S, Clark R, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf T, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason G, Holyoake T, Loges S
CLIN CANCER RES. 2017;23(9):2289-2300.

Catch and Release: rare cell analysis from a functionalised medical wire
Chen S, El-Heliebi A, Tauber G, Langsenlehner T, Pötscher M, Kashofer K, Czyż Z, Polzer B, Riethdorf S, Kuske A, Leitinger G, Pantel K, Kroneis T, Sedlmayr P
SCI REP-UK. 2017;7:43424.

Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
de Gregorio A, Friedl T, Huober J, Scholz C, de Gregorio N, Rack B, Trapp E, Alunni-Fabbroni M, Riethdorf S, Muller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Jaeger B, Hartkopf A, Taran F, Fasching P, Janni W, Fehm T
JCO PRECIS ONCOL. 2017;2017(1):1-12.

PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression
Hohensee I, Chuang H, Grottke A, Werner S, Schulte A, Horn S, Lamszus K, Bartkowiak K, Witzel I, Westphal M, Matschke J, Glatzel M, Jücker M, Pukrop T, Pantel K, Wikman H
ONCOTARGET. 2017;8(4):6155-6168.

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
Jaeger B, Neugebauer J, Andergassen U, Melcher C, Schochter F, Mouarrawy D, Ziemendorff G, Clemens M, V Abel E, Heinrich G, Schueller K, Schneeweiss A, Fasching P, Beckmann M, Scholz C, Friedl T, Friese K, Pantel K, Fehm T, Janni W, Rack B
PLOS ONE. 2017;12(6):e0173593.

PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells
Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, Pantel K, Kronqvist P, Kallioniemi O, Carpèn O, Iljin K
J PATHOL CLIN RES. 2017;3(2):123-138.

Liquid Biopsy: Current Status and Future Perspectives
Mader S, Pantel K
ONCOL RES TREAT. 2017;40(7-8):404-408.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases
Mohme M, Riethdorf S, Dreimann M, Werner S, Maire C, Joosse S, Bludau F, Mueller V, Neves R, Stoecklein N, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker S
SCI REP-UK. 2017;7(1):7196.

Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape
Mohme M, Riethdorf S, Pantel K
NAT REV CLIN ONCOL. 2017;14(3):155-167.

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer
O'Flaherty L, Wikman H, Pantel K
TRANSL LUNG CANCER R. 2017;6(4):431-443.

Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer
Pantel K, Alix-Panabières C
NAT REV GASTRO HEPAT. 2017;14(2):73-74.

Tumour microenvironment: informing on minimal residual disease in solid tumours
Pantel K, Alix-Panabières C
NAT REV CLIN ONCOL. 2017;14(6):325-326.

Cancer stem cells: The root of tumor recurrence and metastases
Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A
SEMIN CANCER BIOL. 2017;44:10-24.

Hamburg-Glasgow classification: preoperative staging by combination of disseminated tumour load and systemic inflammation in oesophageal carcinoma
Reeh M, Ghadban T, Uzunoglu F, Nentwich M, Bockhorn M, Pantel K, Izbicki J, Vashist Y
BRIT J CANCER. 2017;117(5):612-618.

Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial
Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Schem C, von Minckwitz G, Untch M, Pantel K
CLIN CANCER RES. 2017;23(18):5384-5393.

Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer
Schramm A, Schochter F, Friedl T, de Gregorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, Jaeger B, Heinrich G, Camara O, Decker T, Ober A, Mahner S, Fehm T, Pantel K, Fasching P, Schneeweiss A, Janni W, Rack B
CLIN BREAST CANCER. 2017;17(4):279-285.

Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study
Soave A, Chun F, Hillebrand T, Rink M, Weisbach L, Steinbach B, Fisch M, Pantel K, Schwarzenbach H
ONCOTARGET. 2017;8(34):56398-56407.

Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy
Soave A, Riethdorf S, Dahlem R, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M
BJU INT. 2017;119(6):854-861.

A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy
Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, Engel O, Fisch M, Pantel K, Rink M
INT J CANCER. 2017;140(2):381-389.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse A, Riethdorf S, Wege H
ONCOTARGET. 2017;8(52):89978-89987.

Tracing the Seeds in the Soil
Werner S, Pantel K
CLIN CHEM. 2017;63(11):1764-1765.

Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells
Werner S, Stenzl A, Pantel K, Todenhöfer T
ADV EXP MED BIOL. 2017;994:205-228.

Nanoplatforms for Circulating Tumor Cell Detection in Lung Cancer
Wikman H, Pantel K
CLIN CHEM. 2017;63(8):1318-1320.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S
NAT COMMUN. 2017;8(1):269.

Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy
Zheng H, Bae Y, Kasimir-Bauer S, Tang R, Chen J, Ren G, Yuan M, Esposito M, Li W, Wei Y, Shen M, Zhang L, Tupitsyn N, Pantel K, King C, Sun J, Moriguchi J, Jun H, Coxon A, Lee B, Kang Y
CANCER CELL. 2017;32(6):731-747.e6.

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M
BMC CANCER. 2016;16:522.

Functional studies on circulating and disseminated tumor cells in carcinoma patients
Alix-Panabières C, Bartkowiak K, Pantel K
MOL ONCOL. 2016;10(3):443-9.

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières C, Pantel K
CANCER DISCOV. 2016;6(5):479-91.

Cancer: A shocking protein complex
Bartkowiak K, Pantel K
NATURE. 2016;538(7625):322-323.

Potential Involvement of Jagged1 in Metastatic Progression of Human Breast Carcinomas
Bednarz-Knoll N, Efstathiou A, Gotzhein F, Wikman H, Mueller V, Kang Y, Pantel K
CLIN CHEM. 2016;62(2):378-386.

Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer
Deutsch T, Riethdorf S, Nees J, Hartkopf A, Schönfisch B, Domschke C, Sprick M, Schütz F, Brucker S, Stefanovic S, Sohn C, Pantel K, Trumpp A, Schneeweiss A, Wallwiener M
BREAST CANCER RES TR. 2016;160(2):277-290.

Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer
Gasch C, Oldopp T, Mauermann O, Gorges T, Andreas A, Coith C, Müller V, Fehm T, Janni W, Pantel K, Riethdorf S
MOL ONCOL. 2016;10(8):1330-43.

Diverse prognostic value of the GTn promoter polymorphism in squamous cell and adeno carcinoma of the esophageus
Ghadban T, Miro J, Trump F, Tsui T, Uzunoglu F, Reeh M, Gebauer F, Bachmann K, Wellner U, Kalinin V, Pantel K, Izbicki J, Vashist Y
CLIN GENET. 2016;90(4):343-50.

Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells
Gorges T, Kuske A, Röck K, Mauermann O, Müller V, Peine S, Verpoort K, Novosadova V, Kubista M, Riethdorf S, Pantel K
CLIN CHEM. 2016;62(11):1504-1515.

Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells
Gorges T, Penkalla N, Schalk T, Joosse S, Riethdorf S, Tucholski J, Lucke K, Wikman H, Jackson S, Brychter N, von Ahsen O, Schumann C, Krahn T, Pantel K
CLIN CANCER RES. 2016;22(9):2197-206.

Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer
Gorges T, Riethdorf S, von Ahsen O, Nastały P, Röck K, Boede M, Peine S, Kuske A, Schmid E, Kneip C, König F, Rudolph M, Pantel K
ONCOTARGET. 2016;7(23):34930-41.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®
Gorges T, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse S, Pantel K
PLOS ONE. 2016;11(5):e0155126.

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm
Gulley J, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T
ONCOIMMUNOLOGY. 2016;5(4):e1107698.

Characterization of different CTC subpopulations in non-small cell lung cancer
Hanssen A, Wagner J, Gorges T, Tänzer A, Uzunoglu F, Driemel C, Stoecklein N, Knoefel W, Angenendt S, Hauch S, Atanackovic D, Loges S, Riethdorf S, Pantel K, Wikman H
SCI REP-UK. 2016;6:28010.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves R, Stoecklein N, Wikman H, Riethdorf S, Pantel K, Gorges T
INT J CANCER. 2016;138(12):2894-904.

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial
Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart M, Sotiriou C, Litiere S, Pierga J
EUR J CANCER. 2016;63:97-104.

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Janni W, Rack B, Terstappen L, Pierga J, Taran F, Fehm T, Hall C, de Groot M, Bidard F, Friedl T, Fasching P, Brucker S, Pantel K, Lucci A
CLIN CANCER RES. 2016;22(10):2583-93.

Genetic traits for hematogeneous tumor cell dissemination in cancer patients
Joosse S, Pantel K
CANCER METAST REV. 2016;35(1):41-8.

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial
Jueckstock J, Rack B, Friedl T, Scholz C, Steidl J, Trapp E, Tesch H, Forstbauer H, Lorenz R, Rezai M, Häberle L, Alunni-Fabbroni M, Schneeweiss A, Beckmann M, Lichtenegger W, Fasching P, Pantel K, Janni W
BMC CANCER. 2016;16:401.

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients
Kuske A, Gorges T, Tennstedt P, Tiebel A, Pompe R, Preißer F, Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabières C, Riethdorf S, Beyer B, Schlomm T, Pantel K
SCI REP-UK. 2016;6:39736.

Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?
Leung F, Kulasingam V, Diamandis E, Hoon D, Kinzler K, Pantel K, Alix-Panabières C
CLIN CHEM. 2016;62(8):1054-60.

Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis
Madhavan D, Peng C, Wallwiener M, Zucknick M, Nees J, Schott S, Rudolph A, Riethdorf S, Trumpp A, Pantel K, Sohn C, Chang-Claude J, Schneeweiss A, Burwinkel B
CARCINOGENESIS. 2016;37(5):461 - 470.

Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer
Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H
ADV EXP MED BIOL. 2016;924:3-8.

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K, Schwarzenbach H
ONCOTARGET. 2016;7(13):16923-35.

Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer
Meyer C, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S, Steuber T
UROL ONCOL-SEMIN ORI. 2016;34(5):235.e11-6.

Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection
Pantel K
PLOS MED. 2016;13(12):e1002205.

TP53 mutations on circulating cell-free DNA
Pantel K
EBIOMEDICINE. 2016;10:15-6.

Functional Studies on Viable Circulating Tumor Cells
Pantel K, Alix-Panabières C
CLIN CHEM. 2016;62(2):328-34.

Liquid biopsy: Potential and challenges
Pantel K, Alix-Panabières C
MOL ONCOL. 2016;10(3):371-3.

The biology of circulating tumor cells
Pantel K, Speicher M
ONCOGENE. 2016;35(10):1216-24.

Plasma S100P level as a novel prognostic marker of metastatic breast cancer
Peng C, Chen H, Wallwiener M, Modugno C, Cuk K, Madhavan D, Trumpp A, Heil J, Marmé F, Nees J, Riethdorf S, Schott S, Sohn C, Pantel K, Schneeweiss A, Yang R, Burwinkel B
BREAST CANCER RES TR. 2016;157(2):329-38.

Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer
Peng C, Wallwiener M, Rudolph A, Ćuk K, Eilber U, Celik M, Modugno C, Trumpp A, Heil J, Marmé F, Madhavan D, Nees J, Riethdorf S, Schott S, Sohn C, Pantel K, Schneeweiss A, Chang-Claude J, Yang R, Burwinkel B
INT J CANCER. 2016;138(10):2499-509.

Liquid biopsies for surveillance and monitoring treatment response of bladder cancer
Riethdorf S, Pantel K
J TRANSL MED. 2016;4(19):379.

Chronic UVB-irradiation actuates perpetuated dermal matrix remodeling in female mice: Protective role of estrogen
Röck K, Joosse S, Müller J, Heinisch N, Fuchs N, Meusch M, Zipper P, Reifenberger J, Pantel K, Fischer J
SCI REP-UK. 2016;6:30482.

Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy
Schlange T, Pantel K
PHARMACOGENOMICS. 2016;17(3):183-6.

Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program
Schramm A, Friedl T, Schochter F, Scholz C, de Gregorio N, Huober J, Rack B, Trapp E, Alunni-Fabbroni M, Müller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Hartkopf A, Taran F, Wallwiener D, Janni W, Fehm T
ARCH GYNECOL OBSTET. 2016;293(2):271-81.

RHAMM splice variants confer radiosensitivity in human breast cancer cell lines
Schütze A, Vogeley C, Gorges T, Twarock S, Butschan J, Babayan A, Klein D, Knauer S, Metzen E, Müller V, Jendrossek V, Pantel K, Milde-Langosch K, Fischer J, Röck K
ONCOTARGET. 2016;7(16):21428-40.

Breast cancer brain metastases:biology and new clinical perspectives
Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H
BREAST CANCER RES. 2016;18(1):8.

Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay
Alix-Panabières C, Pantel K
EXPERT REV MOL DIAGN. 2015;15(11):1411-7.

Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response
Bartkowiak K, Kwiatkowski M, Buck F, Gorges T, Nilse L, Assmann V, Andreas A, Müller V, Wikman H, Riethdorf S, Schlüter H, Pantel K
CANCER RES. 2015;75(24):5367-77.

Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression
Bednarz-Knoll N, Nastały P, Żaczek A, Stoupiec M, Riethdorf S, Wikman-Kocher H, Müller V, Skokowski J, Szade J, Sejda A, Wełnicka-Jaśkiewicz M, Pantel K
ONCOTARGET. 2015;6(29):26789-803.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

A Versatile Microarray Platform for Capturing Rare Cells
Brinkmann F, Hirtz M, Haller A, Gorges T, Vellekoop M, Riethdorf S, Müller V, Pantel K, Fuchs H
SCI REP-UK. 2015;5:Art. 15342.

Establishment and characterization of a cell line from human circulating colon cancer cells
Cayrefourcq L, Mazard T, Joosse S, Solassol J, Ramos J, Assenat E, Schumacher U, Costes V, Maudelonde T, Pantel K, Alix-Panabières C
CANCER RES. 2015;75(5):892-901.

Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells
Gasch C, Pantel K, Riethdorf S
Methods Mol Biol. 2015;1347:221-32.

Heterogeneity of miR-10b expression in circulating tumor cells
Gasch C, Plummer P, Jovanovic L, McInnes L, Wescott D, Saunders C, Schneeweiss A, Wallwiener M, Nelson C, Spring K, Riethdorf S, Thompson E, Pantel K, Mellick A
SCI REP-UK. 2015;5:Art. 15980.

Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer
Ghadban T, Schmidt-Yang M, Uzunoglu F, Perez D, El Gammal A, Miro J, Wellner U, Pantel K, Izbicki J, Vashist Y
CANCER GENET-NY. 2015;208(12):595–601.

Correction to: An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer
Ghadban T, Schmidt-Yang M, Uzunoglu F, Perez D, Tsui T, El Gammal A, Erbes P, Zilbermints V, Wellner U, Pantel K, Izbicki J, Vashist Y
J HUM GENET. 2015;60(2):107.

„Liquid Biopsy“ – Nachweis und Charakterisierung von zirkulierenden Tumorzellen
Gorges T, Riethdorf S, Pantel K
2015.

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
Hanssen A, Loges S, Pantel K, Wikman-Kocher H
FRONT ONCOL. 2015;5:Art. 207.

Tumour exosome integrins determine organotropic metastasis
Hoshino A, Costa-Silva B, Shen T, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies A, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss J, Dumont-Cole V, Kramer K, Wexler L, Narendran A, Schwartz G, Healey J, Sandstrom P, Jørgen Labori K, Kure E, Grandgenett P, Hollingsworth M, de Sousa M, Kaur S, Jain M, Mallya K, Batra S, Jarnagin W, Brady M, Fodstad O, Muller V, Pantel K, Minn A, Bissell M, Garcia B, Kang Y, Rajasekhar V, Ghajar C, Matei I, Peinado H, Bromberg J, Lyden D
NATURE. 2015;527(7578):329-35.

Biology, detection, and clinical implications of circulating tumor cells
Joosse S, Gorges T, Pantel K
EMBO MOL MED. 2015;7(1):1-11.

Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients
Joosse S, Pantel K
CANCER CELL. 2015;28(5):552-4.

Mutant p53 promotes epithelial-mesenchymal plasticity and enhances metastasis in mammary carcinomas of WAP-T mice
Lenfert E, Mänz C, Heinlein C, Jannasch K, Schumacher U, Pantel K, Tolstonog G, Deppert W, Wegwitz F
INT J CANCER. 2015;136(6):E521-E533.

Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells
Maenz C, Lenfert E, Pantel K, Schumacher U, Deppert W, Wegwitz F
BMC CANCER. 2015;15:178.

Frequent expression of PD-L1 on circulating breast cancer cells
Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C
MOL ONCOL. 2015;9(9):1773-82.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
Meng X, Joosse S, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H
BRIT J CANCER. 2015;113(9):1358-1366.

Relevance of βGal-βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients
Milde-Langosch K, Schütze D, Oliveira-Ferrer L, Wikman-Kocher H, Müller V, Lebok P, Pantel K, Schröder C, Witzel I, Schumacher U
BREAST CANCER RES TR. 2015;151(3):515-28.

Disseminierte und zirkulierende Tumorzellen, zirkulierende DNA und RNA im Blut - Biomarker beim Mammakarzinom?
Muller V, Riethdorf S, Pantel K
2015. Tumorbiologie und Diagnostik des primären Mammakarzinoms. Vetter M, Kantelhardt E (eds.). 1. ed. Bremen: Uni-Med, 84-91.

Cell lines from circulating tumor cells: Comment on: Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. Cancer Res. 2015 Mar 1; 75(5): 892-901
Pantel K, Alix-Panabières C
Oncoscience. 2015;2(10):815-6.

Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer
Reeh M, Harms-Effenberger K, Koenig A, Riethdorf S, Eichstädt D, Vettorazzi E, Uzunoglu F, Vashist Y, Izbicki J, Pantel K, Bockhorn M
ANN SURG. 2015;261(6):1124-30.

Diverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues
Riethdorf S, Frey S, Santjer S, Stoupiec M, Otto B, Riethdorf L, Koop C, Wilczak W, Simon R, Sauter G, Pantel K, Assmann V
INT J CANCER. 2015;138:949-963.

Data Normalization Strategies for MicroRNA Quantification
Schwarzenbach H, Machado da Silva A, Calin G, Pantel K
CLIN CHEM. 2015;61(11):1333-42.

Circulating DNA as biomarker in breast cancer
Schwarzenbach H, Pantel K
BREAST CANCER RES. 2015;17:Art. 136.

Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy?
Soave A, Riethdorf S, Pantel K, Fisch M, Rink M
CURR UROL REP. 2015;16(7):Art. 46.

Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients
Stückrath I, Rack B, Janni W, Jäger B, Pantel K, Schwarzenbach H
ONCOTARGET. 2015;6(15):13387-401.

Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer
Ueo H, Sugimachi K, Gorges T, Bartkowiak K, Yokobori T, Müller V, Shinden Y, Ueda M, Ueo H, Mori M, Kuwano H, Maehara Y, Ohno S, Pantel K, Mimori K
BRIT J CANCER. 2015;112(9):1519-26.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
Wallwiener M, Hartkopf A, Riethdorf S, Nees J, Sprick M, Schönfisch B, Taran F, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A
BMC CANCER. 2015;15:Art. 403.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic acid induced 2
Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood A, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen S, Klefstrom J, Wilmanns M, Müller V, Pantel K, Wikman-Kocher H
CANCER DISCOV. 2015;5(5):506-19.

Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells
Werner S, Stamm H, Pandjaitan M, Kemming D, Brors B, Pantel K, Wikman H
BMC CANCER. 2015;15(1):896.

Identification of HERC5 and its potential role in NSCLC progression
Wrage M, Hagmann W, Kemming D, Uzunoglu F, Riethdorf S, Harms-Effenberger K, Westphal M, Lamszus K, Kim S, Becker N, Izbicki J, Sandoval J, Esteller M, Pantel K, Risch A, Wikman-Kocher H
INT J CANCER. 2015;136(10):2264-72.

[The Circulating Tumor Cells: Liquid Biopsy of Cancer]
Alix-Panabieres C, Pantel K
Klinicheskaia laboratornaia diagnostika. 2014;(4):60-4.

Opinion: Challenges in circulating tumour cell research
Alix-Panabières C, Pantel K
NAT REV CANCER. 2014;14(9):623-631.

Technologies for detection of circulating tumor cells: facts and vision
Alix-Panabières C, Pantel K
LAB CHIP. 2014;14(1):57-62.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data: a pooled analysis of individual patient data
Bidard F, Peeters D, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti A, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere S, Meier-Stiegen F, Sandri M, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson S, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer E, Zorzino L, Johannes H, Reis-Filho J, Pantel K, Pierga J, Michiels S
LANCET ONCOL. 2014;15(4):406-414.

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
Eichelser C, Stückrath I, Müller V, Milde-Langosch K, Wikman-Kocher H, Pantel K, Schwarzenbach H
ONCOTARGET. 2014;5(20):9650-63.

Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer
Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto G, De Falco E, Nicolazzo C, Giovannone R, Gentile V, Cortesi E, Pantel K
INT J CANCER. 2014;135(8):1978-1982.

An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer
Ghadban T, Schmidt-Yang M, Uzunoglu F, Perez D, Tsui T, El Gammal A, Erbes P, Zilbermints V, Wellner U, Pantel K, Izbicki J, Vashist Y
J HUM GENET. 2014;59(12):661-666.

Pathogenesis of Minimal Residual Disease: CTCs as Novel Biomarkers in Cancer Disease
Gorges T, Pantel K
2014.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice
Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M
CELL SIGNAL. 2014;26(5):1021-9.

Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity
Gröbe A, Blessmann M, Hanken H, Friedrich R, Schön G, Wikner J, Harms-Effenberger K, Kluwe L, Heiland M, Pantel K, Riethdorf S
CLIN CANCER RES. 2014;20(2):425-33.

The dynamic range of circulating tumor DNA in metastatic breast cancer
Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl J, Speicher M
BREAST CANCER RES. 2014;16(4):421.

International study on inter-reader variability for circulating tumor cells in breast cancer
Ignatiadis M, Riethdorf S, Bidard F, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne R, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, Bessi S, Pestrin M, Di Leo A, Campion M, Reinholz M, Perez E, Piccart M, Borgen E, Naume B, Jimenez J, Aura C, Zorzino L, Cassatella M, Sandri M, Mostert B, Sleijfer S, Kraan J, Janni W, Fehm T, Rack B, Terstappen L, Repollet M, Pierga J, Miller C, Sotiriou C, Michiels S, Pantel K
BREAST CANCER RES. 2014;16(2):R43.

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
Joosse S, Müller V, Steinbach B, Pantel K, Schwarzenbach H
BRIT J CANCER. 2014;111(5):909-17.

PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis
LeBleu V, O'Connell J, Gonzalez Herrera K, Wikman-Kocher H, Pantel K, Haigis M, de Carvalho F, Damascena A, Domingos Chinen L, Rocha R, Asara J, Kalluri R
NAT CELL BIOL. 2014;16(10):992-1003.

Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis
Madhavan D, Wallwiener M, Bents K, Zucknick M, Nees J, Schott S, Cuk K, Riethdorf S, Trumpp A, Pantel K, Sohn C, Schneeweiss A, Surowy H, Burwinkel B
BREAST CANCER RES TR. 2014;146(1):163-174.

Circulating tumor cells in head and neck cancer: clinical impact in diagnosis and follow-up
Möckelmann N, Laban S, Pantel K, Knecht R
EUR ARCH OTO-RHINO-L. 2014;271(1):15-21.

Hematogenous dissemination of glioblastoma multiforme
Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher M, Geigl J, Westphal M, Pantel K, Riethdorf S
SCI TRANSL MED. 2014;6(247):247ra101.

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial
Müller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M, Schwedler K, Lübbe K, Schem C, Fasching P, Mau C, Pantel K, Schwarzenbach H
BREAST CANCER RES TR. 2014;147(1):61-8.

Circulating tumor cells in patients with testicular germ cell tumors
Nastały P, Ruf C, Becker P, Bednarz-Knoll N, Stoupiec M, Kavsur R, Isbarn H, Matthies C, Wagner W, Höppner D, Fisch M, Bokemeyer C, Ahyai S, Honecker F, Riethdorf S, Pantel K
CLIN CANCER RES. 2014;20(14):3830-41.

Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients: a special source for liquid biopsy in cancer patients
Pantel K, Alix-Panabières C
Bonekey Rep. 2014;3:584.

Circulating tumor cells predict survival in early average-to-high risk breast cancer patients
Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, Friedl T, Lorenz R, Tesch H, Fasching P, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann M, Friese K, Pantel K, Janni W
JNCI-J NATL CANCER I. 2014;106(5):.

Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients
Ramirez J, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K, Alix-Panabières C
CLIN CHEM. 2014;60(1):214-221.

Erratum zu: Detektion und Stellenwert von zirkulierenden Tumorzellen im peripheren Blut beim Urothelkarzinom der Harnblase
Rink M, Soave A, Engel O, Fisch M, Riethdorf S, Pantel K
UROLOGE. 2014;53(5):740.

Zirkulierende Tumorzellen im peripheren Blut beim Urothelkarzinom der Harnblase: Detektion und Stellenwert
Rink M, Soave A, Engel O, Fisch M, Riethdorf S, Pantel K
UROLOGE. 2014;53(4):501-508.

Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein
Schwarzenbach H, Eichelser C, Steinbach B, Tadewaldt J, Pantel K, Lobanenkov V, Loukinov D
BMC CANCER. 2014;14:796.

Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach H, Nishida N, Calin G, Pantel K
NAT REV CLIN ONCOL. 2014;11(3):145-156.

Circulating MicroRNAs as Non-Invasive Biomarkers
Schwarzenbach H, Pantel K
2014. MicroRNAs in Medicine. Lawrie C (eds.). 1. ed. Wiley-Blackwell, 567-588.

Tumor signatures in the blood
Speicher M, Pantel K
NAT BIOTECHNOL. 2014;32(5):441-3.

Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer
Tachezy M, Tiebel A, Gebauer F, Kutup A, Tharun L, Pantel K, Izbicki J, Vashist Y
HISTOPATHOLOGY. 2014;29(11):1467-1475.

Loss of 4q21.23-22.1 is a Prognostic Marker for Disease Free and Overall Survival in Non-Small Cell Lung Cancer
Uzunoglu F, Dethlefsen E, Hanssen A, Wrage M, Deutsch L, Harms-Effenberger K, Vashist Y, Reeh M, Sauter G, Simon R, Bockhorn M, Pantel K, Izbicki J, Wikman-Kocher H
PLOS ONE. 2014;9(12):e113315.

EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer
Vashist Y, Trump F, Gebauer F, Kutup A, Güngör C, Kalinin V, Muddasar R, Vettorazzi E, Yekebas E, Brandt B, Pantel K, Izbicki J
TARGET ONCOL. 2014;9(1):43-52.

Serial enumeration of circulating tumor cells predicts treatment response andprognosis in metastatic breast cancer: a prospective study in 393 patients
Wallwiener M, Riethdorf S, Hartkopf A, Modugno C, Nees J, Madhavan D, Sprick M, Schott S, Domschke C, Baccelli I, Schönfisch B, Burwinkel B, Marmé F, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A
BMC CANCER. 2014;14:512.

Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients
Wikman-Kocher H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal M, Iljin K, Huhtala H, Terracciano L, Kallioniemi A, Sauter G, Müller V, Witzel I, Lamszus K, Kemming D, Pantel K
ONCOTARGET. 2014;5(10):3076-3087.

Squamous cell carcinoma of the oral cavity and circulating tumour cells
Wikner J, Gröbe A, Pantel K, Riethdorf S
WORLD J CLIN ONCOL. 2014;5(2):114-124.

Circulating tumor cells: liquid biopsy of cancer.
Alix-Panabières C, Pantel K
CLIN CHEM. 2013;59(1):110-118.

Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA
Alix-Panabières C, Pantel K
J TRANSL MED. 2013;1(2):18.

Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients
Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse S
PLOS ONE. 2013;8(9):e75038.

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn H, Pantel K, Weichert W, Trumpp A
NAT BIOTECHNOL. 2013;31(6):539-44.

Definition of molecular determinants of prostate cancer cell bone extravasation.
Barthel S, Hays D, Yazawa E, Opperman M, Walley K, Nimrichter L, Burdick M, Gillard B, Moser M, Pantel K, Foster B, Pienta K, Dimitroff C
CANCER RES. 2013;73(2):942-952.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Capture of viable circulating tumor cells in the liver of colorectal cancer patients
Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès J, Maudelonde T, Fabre J, Pantel K, Alix-Panabières C
CLIN CHEM. 2013;59(9):1384-92.

Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression
Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H
CLIN CHEM. 2013;59(10):1489-96.

Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis
Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y
CANCER CELL. 2013;24(4):542-56.

Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert A, Mauermann O, Izbicki J, Pantel K, Riethdorf S
CLIN CHEM. 2013;59(1):252-260.

Circulating tumor cells as therapy-related biomarkers in cancer patients.
Gorges T, Pantel K
CANCER IMMUNOL IMMUN. 2013;62(5):931-939.

Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer
Grob T, Hoenig T, Clauditz T, Atanackovic D, Koenig A, Vashist Y, Klose H, Simon R, Pantel K, Izbicki J, Bokemeyer C, Sauter G, Wilczak W
LUNG CANCER. 2013;79(3):221-7.

Correction: Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal Cancer
Gros S, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, Harms-Effenberger K, Reichelt U, Hoffmann R, Pantel K, Kaifi J, Izbicki J
PLOS ONE. 2013;8(5):.

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing
Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann E, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl J, Speicher M
CANCER RES. 2013;73(10):2965-75.

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer
Heitzer E, Auer M, Hoffmann E, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Höfler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl J, Speicher M
INT J CANCER. 2013;133(2):346-56.

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, Benezeder T, Auer M, Pischler C, Mannweiler S, Pichler M, Eisner F, Haeusler M, Riethdorf S, Pantel K, Samonigg H, Hoefler G, Augustin H, Geigl J, Speicher M
GENOME MED. 2013;5(4):30.

Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases
Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, Witzel I, Westphal M, Brandt B, Müller V, Pantel K, Wikman H
AM J PATHOL. 2013;183(1):83-95.

Functional activity of RLIM/Rnf12 is regulated by phosphorylation-dependent nucleocytoplasmic shuttling
Jiao B, Taniguchi-Ishigaki N, Güngör C, Peters M, Chen Y, Riethdorf S, Drung A, Ahronian L, Shin J, Pagnis R, Pantel K, Tachibana T, Lewis B, Johnsen S, Bach I
MOL BIOL CELL. 2013;24(19):3085-96.

Biologic challenges in the detection of circulating tumor cells.
Joosse S, Pantel K
CANCER RES. 2013;73(1):8-11.

Tumor cell dissemination: emerging biological insights from animal models and cancer patients
Kang Y, Pantel K
CANCER CELL. 2013;23(5):573-81.

Patterns of metastatic spread in early breast cancer
Klevesath M, Pantel K, Agbaje O, Provenzano E, Wishart G, Gough P, Pinder S, Duffy S, Purushotham A
BREAST. 2013;22(4):449-54.

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions
Kluth M, Hesse J, Heinl A, Krohn A, Steurer S, Sirma H, Simon R, Mayer P, Schumacher U, Grupp K, Izbicki J, Pantel K, Dikomey E, Korbel J, Plass C, Sauter G, Schlomm T, Minner S
MODERN PATHOL. 2013;26(7):975-83.

Advances in circulating tumor cells (ACTC): from basic research to clinical practice
Lianidou E, Mavroudis D, Pantel K
BREAST CANCER RES. 2013;15(6):319.

Low-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression.
Otto B, Gruner K, Heinlein C, Wegwitz F, Nollau P, Ylstra B, Pantel K, Schumacher U, Baumbusch L, Martin-Subero J, Siebert R, Wagener C, Streichert T, Deppert W, Tolstonog G
INT J CANCER. 2013;132(6):1300-1310.

Real-time liquid biopsy in cancer patients: fact or fiction?
Pantel K, Alix-Panabières C
CANCER RES. 2013;73(21):6384-8.

Tracking tumor resistance using 'liquid biopsies'
Pantel K, Diaz L, Polyak K
NAT MED. 2013;19(6):676-677.

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma
Schulze K, Gasch C, Staufer K, Nashan B, Lohse A, Pantel K, Riethdorf S, Wege H
INT J CANCER. 2013;133(9):2165-71.

CXCR7 expression in esophageal cancer
Tachezy M, Zander H, Gebauer F, Loga K, Pantel K, Izbicki J, Bockhorn M
J TRANSL MED. 2013;11:238.

C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC
Uzunoglu F, Yavari N, Bohn B, Nentwich M, Reeh M, Pantel K, Perez D, Tsui T, Bockhorn M, Mann O, Izbicki J, Wikman H, Vashist Y
LUNG CANCER. 2013;81(1):123-9.

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M, Hartkopf A, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer E, Müller V, Janni W, Schneeweiss A, Fehm T
BREAST CANCER RES TR. 2013;137(2):503-510.

Tumor metastasis: moving new biological insights into the clinic
Wan L, Pantel K, Kang Y
NAT MED. 2013;19(11):1450-64.

Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer
Werner S, Frey S, Riethdorf S, Schulze C, Alawi M, Kling L, Vafaizadeh V, Sauter G, Terracciano L, Schumacher U, Pantel K, Assmann V
J BIOL CHEM. 2013;288(32):22993-3008.

Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis
Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, Nishida N, Kogo R, Sudo T, Tanaka F, Shibata K, Toh H, Sato T, Barnard G, Fukagawa T, Yamamoto S, Nakanishi H, Sasaki S, Miyano S, Watanabe T, Kuwano H, Mimori K, Pantel K, Mori M
CANCER RES. 2013;73(7):2059-69.

Circulating tumor cells and circulating tumor DNA.
Alix-Panabières C, Schwarzenbach H, Pantel K
ANNU REV MED. 2012;63:199-215.

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination
Balz L, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker K, Brandt B, Dittmar T
J PATHOL. 2012;227(2):234-244.

The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis.
Bartkowiak K, Riethdorf S, Pantel K
CANCER MICROENVIRON. 2012;5(1):59-72.

Plasticity of disseminating cancer cells in patients with epithelial malignancies.
Bednarz N, Alix-Panabières C, Pantel K
CANCER METAST REV. 2012;31(3-4):673-687.

Immunocytochemical detection and characterisation of individual micrometastatic tumour cells.
Braun S, Pantel K
Methods Mol Biol. 2012;878:63-70.

Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.
Deutsch L, Wrage M, Koops S, Glatzel M, Uzunoglu F, Kutup A, Hinsch A, Sauter G, Izbicki J, Pantel K, Wikman H
GENE CHROMOSOME CANC. 2012;51(6):618-629.

Zirkulierende Tumorzellen in Krebspatienten als neuer Biomarker
Gorges T, Riethdorf S, Pantel K
J Onkol - Z Onkol Fortb. 2012;(7):184-188.

Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.
Gros S, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, Harms-Effenberger K, Reichelt U, Hoffman R, Pantel K, Kaifi J, Izbicki J
PLOS ONE. 2012;7(10):47287.

Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival.
Harms-Effenberger K, Schröder C, Zu Eulenburg C, Reeh M, Tachezy M, Riethdorf S, Vashist Y, Izbicki J, Pantel K, Bockhorn M
INT J CANCER. 2012;131(4):475-483.

Minimal residual disease and circulating tumor cells in breast cancer: open questions for research.
Ignatiadis M, Sotiriou C, Pantel K
Recent Results Cancer Res. 2012;195:3-9.

Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.
Joosse S, Hannemann J, Spötter J, Bauche A, Andreas A, Müller V, Pantel K
CLIN CANCER RES. 2012;18(4):993-1003.

15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells.
Lehtinen L, Vainio P, Wikman H, Reemts J, Hilvo M, Issa R, Pollari S, Brandt B, Oresic M, Pantel K, Kallioniemi O, Iljin K
J PATHOL. 2012;226(4):674-686.

Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, Burwinkel B
CLIN CANCER RES. 2012;18(21):5972-5982.

High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer.
Mathiesen R, Fjelldal R, Liestøl K, Due E, Geigl J, Riethdorf S, Borgen E, Rye I, Schneider I, Obenauf A, Mauermann O, Nilsen G, Ole C, Børresen-Dale A, Pantel K, Speicher M, Naume B, Baumbusch L
INT J CANCER. 2012;131(4):405-415.

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T, Group O
BREAST CANCER RES. 2012;14(4):118.

Detection methods of circulating tumor cells.
Pantel K, Alix-Panabières C
J THORAC DIS. 2012;4(5):446-447.

The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer.
Pantel K, Alix-Panabières C
CANCER DISCOV. 2012;2(11):974-975.

Circulating epithelial cells in patients with benign colon diseases.
Pantel K, Denève E, Nocca D, Coffy A, Vendrell J, Maudelonde T, Riethdorf S, Alix-Panabières C
CLIN CHEM. 2012;58(5):936-940.

Considerations in the development of circulating tumor cell technology for clinical use.
Parkinson D, Dracopoli N, Petty B, Compton C, Cristofanilli M, Deisseroth A, Hayes D, Kapke G, Kumar P, Lee J, Liu M, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose E, Roadcap L, Schade A, Scher H, Sigman C, Kelloff G
J TRANSL MED. 2012;10:138.

Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
Rink M, Chun F, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth L, Ahyai S, Friedrich M, Shariat S, Fisch M, Pantel K, Riethdorf S
EUR UROL. 2012;61(4):810-817.

Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
Roth C, Stückrath I, Pantel K, Izbicki J, Tachezy M, Schwarzenbach H
PLOS ONE. 2012;7(6):38248.

The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.
Saad F, Pantel K
FUTURE ONCOL. 2012;8(3):321-331.

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
Schultze A, Ben-Batalla I, Riethdorf S, Bubenheim M, Yekebas E, Erbersdobler A, Reichelt U, Harms-Effenberger K, Schmidt T, Izbicki J, Bokemeyer C, Pantel K, Fiedler W, Loges S
CLIN EXP METASTAS. 2012;29(8):879-887.

Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.
Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K
CLIN CANCER RES. 2012;18(20):5719-5730.

Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients.
Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K
BREAST CANCER RES TR. 2012;134(3):933-941.

The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications.
Sleeman J, Cady B, Pantel K
CLIN EXP METASTAS. 2012;29(7):737-746.

ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients
Tachezy M, Harms-Effenberger K, Zander H, Minner S, Gebauer F, Vashist Y, Sauter G, Pantel K, Izbicki J, Bockhorn M
INT J CANCER. 2012;131(2):396-405.

Circulating tumor-derived biomarkers in lung cancer.
Tänzer A, Alix-Panabières C, Wikman H, Pantel K
J THORAC DIS. 2012;4(5):448-449.

Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
Uzunoglu F, Kaufmann C, Wikman H, Güngör C, Bohn B, Nentwich M, Reeh M, Pantel K, Bockhorn M, Kutup A, Mann O, Izbicki J, Vashist Y
ANN SURG ONCOL. 2012;19(7):2159-2168.

Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer.
Vashist Y, Harms-Effenberger K, Vettorazzi E, Riethdorf S, Yekebas E, Izbicki J, Pantel K
ANN SURG. 2012;255(6):1105-1112.

Relevance of PTEN loss in brain metastasis formation in breast cancer patients.
Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Müller V, Westphal M, Pantel K
BREAST CANCER RES. 2012;14(2):49.

Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
Wikman H, Sielaff-Frimpong B, Kropidlowski J, Witzel I, Milde-Langosch K, Sauter G, Westphal M, Lamszus K, Pantel K
PLOS ONE. 2012;7(10):47537.

Meta-analysis of the prognostic value of circulating tumor cells in breast cancer.
Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, Liu J, Pantel K
CLIN CANCER RES. 2012;18(20):5701-5710.

Clinical relevance and biology of circulating tumor cells.
Bednarz N, Alix-Panabières C, Pantel K
BREAST CANCER RES. 2011;13(6):228.

Circulating tumors cells as biomarkers: progress toward biomarker qualification.
Danila D, Pantel K, Fleisher M, Scher H
CANCER J. 2011;17(6):438-450.

Circulating cancer cells and their clinical applications.
Diamandis E, Pantel K, Scher H, Terstappen L, Lianidou E
CLIN CHEM. 2011;57(11):1478-1484.

Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells
Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jücker M
CELL SIGNAL. 2011;23(12):1952-1960.

Quantitative high-resolution genomic analysis of single cancer cells.
Hannemann J, Meyer-Staeckling S, Kemming D, Alpers I, Joosse S, Pospisil H, Kurtz S, Görndt J, Püschel K, Riethdorf S, Pantel K, Brandt B
PLOS ONE. 2011;6(11):26362.

Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern.
Harms-Effenberger K, Borgen E, Zu Eulenburg C, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland J, Pantel K, Naume B
BREAST CANCER RES TR. 2011;125(3):729-738.

Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S, Müller V, Köhler N, Wikman H, Krenkel S, Streichert T, Schweizer M, Riethdorf S, Assmann V, Henningsen M, Beck K, Issa R, Jänicke F, Pantel K, Milde-Langosch K
BREAST CANCER RES TR. 2011;129(2):347-360.

Molecular mechanisms of metastasis.
Hoon D, Ferris R, Tanaka R, Chong K, Alix-Panabières C, Pantel K
J SURG ONCOL. 2011;103(6):508-517.

Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.
Janni W, Vogl F, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B
CLIN CANCER RES. 2011;17(9):2967-2976.

The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
Karkera J, Steiner H, Li W, Skradski V, Moser P, Riethdorf S, Reddy M, Puchalski T, Safer K, Prabhakar U, Pantel K, Qi M, Culig Z
PROSTATE. 2011;71(13):1455-1465.

Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression.
Kornfeld J, Meder S, Wohlberg M, Friedrich R, Rau T, Riethdorf L, Löning T, Pantel K, Riethdorf S
BRIT J CANCER. 2011;104(1):138-145.

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.
Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede B, Lu X, Haffty B, Pantel K, Massagué J, Kang Y
CANCER CELL. 2011;20(6):701-714.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S, Enodien M, Sirma H, Lübke A, Krohn A, Mayer P, Simon R, Tennstedt P, Müller J, Scholz L, Brase J, Liu A, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T
CLIN CANCER RES. 2011;17(18):5878-5888.

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V, Riethdorf S, Rack B, Janni W, Fasching P, Solomayer E, Aktas B, Kasimir-Bauer S, Zeitz J, Pantel K, Fehm T, Group D
BREAST CANCER RES. 2011;13(4):71.

Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S, Hoegel B, John B, Ott G, Fritz P, Thon S, Löning T, Pantel K
J CANCER RES CLIN. 2011;137(2):261-269.

Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer.
Rink M, Chun F, Minner S, Friedrich M, Mauermann O, Heinzer H, Huland H, Fisch M, Pantel K, Riethdorf S
BJU INT. 2011;107(10):1668-1675.

Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.
Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H
MOL ONCOL. 2011;5(3):281-291.

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression.
Roth C, Pantel K, Müller V, Rack B, Kasimir-Bauer S, Janni W, Schwarzenbach H
BMC CANCER. 2011;11:4.

Circulating microRNAs: promising breast cancer biomarkers - author´s response
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H
BREAST CANCER RES. 2011;13(1):403.

Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ.
Sänger N, Harms-Effenberger K, Riethdorf S, Viviane V, Gauwerky J, Wiegratz I, Strebhardt K, Kaufmann M, Pantel K
INT J CANCER. 2011;129(10):2522-2526.

Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients.
Schwarzenbach H, Chun F, Isbarn H, Huland H, Pantel K
J CANCER RES CLIN. 2011;137(5):811-819.

Cell-free nucleic acids as biomarkers in cancer patients.
Schwarzenbach H, Hoon D, Pantel K
NAT REV CANCER. 2011;11(6):426-437.

Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease.
Schwarzenbach H, Müller V, Milde-Langosch K, Steinbach B, Pantel K
MOL BIOSYST. 2011;7(10):2848-2854.

Controversies in clinical cancer dormancy.
Uhr J, Pantel K
P NATL ACAD SCI USA. 2011;108(30):12396-12400.

Circulating tumor cell isolation and diagnostics: toward routine clinical use.
van de Stolpe A, Pantel K, Sleijfer S, Terstappen L, Toonder d, Jaap M
CANCER RES. 2011;71(18):5955-5960.

The GNAS1 T393C single nucleotide polymorphism predicts the natural postoperative course of complete resected esophageal cancer.
Vashist Y, Kutup A, Musici S, Yekebas E, Mina S, Uzunoglu F, Zehler O, König A, Cataldegirmen G, Bockhorn M, Harms-Effenberger K, Kalinin V, Pantel K, Izbicki J
MOL CELL ONCOL. 2011;34(4):281-288.

Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H
INT J CANCER. 2011;128(11):2572-2580.

Detection of circulating tumor cells by RT-PCR significantly associated with poor prognosis in breast cancer.
Zhang L, Wu G, Pantel K
BREAST CANCER RES TR. 2011;130(1):359-364.

Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients.
Bartkowiak K, Harms-Effenberger K, Harder S, Andreas A, Buck F, Peter-Katalinic J, Pantel K, Brandt B
J PROTEOME RES. 2010;9(6):3158-3168.

BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood
Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A, Mulder L, Hannemann J, Fisch M, Pantel K, Weier H, Bielawski K, Brandt B
CLIN CANCER RES. 2010;16(13):3340-3348.

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
Fehm T, Müller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Löhberg C, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K
BREAST CANCER RES TR. 2010;124(2):403-412.

Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
Kalinina T, Bockhorn M, Kaifi J, Thieltges S, Güngör C, Harms-Effenberger K, Strelow A, Reichelt U, Sauter G, Pantel K, Izbicki J, Yekebas E
INT J CANCER. 2010;127(8):1931-1940.

What's new on circulating tumor cells? A meeting report.
Lianidou E, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K
BREAST CANCER RES. 2010;12(4):307.

Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
Müller I, Wischnewski F, Pantel K, Schwarzenbach H
BMC CANCER. 2010;10:297.

Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies.
Müller V, Alix-Panabières C, Pantel K
EUR J CANCER. 2010;46(7):1189-1197.

Circulating tumour cells in cancer patients: challenges and perspectives.
Pantel K, Alix-Panabières C
TRENDS MOL MED. 2010;16(9):398-406.

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K
CLIN CANCER RES. 2010;16(9):2634-2645.

Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells.
Riethdorf S, Pantel K
ANN NY ACAD SCI. 2010;1210:66-77.

Increase in circulating microRNA levels in blood of ovarian cancer patients
Roth C, Kasimir-Bauer S, Heubner M, Pantel K, Schwarzenbach H
2010. Circulating nucleic acids in plasma and serum. Gahan P (eds.). 1.. ed. Springer, 63-71.

Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
Roth C, Rack B, Müller V, Janni W, Pantel K, Schwarzenbach H
BREAST CANCER RES. 2010;12(6):90.

Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma.
Schwarzenbach H, Goekkurt E, Pantel K, Aust D, Stoehlmacher J
INT J CANCER. 2010;127(4):881-888.

PSA and Prostate
Schwarzenbach H, Pantel K
2010. PSA and Prostate. Nova Science Publishers, 65-85.

Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.
Alix-Panabières C, Vendrell J, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K
BREAST CANCER RES. 2009;11(3):39.

Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/ progenitor cell protein profile.
Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Harms-Effenberger K, Pantel K, Peter-Katalinic J, Brandt B
J PROTEOME RES. 2009;8(4):2004-2014.

Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer.
Johnsen S, Güngör C, Prenzel T, Riethdorf S, Riethdorf L, Taniguchi-Ishigaki N, Rau T, Tursun B, Furlow J, Sauter G, Scheffner M, Pantel K, Gannon F, Bach I
CANCER RES. 2009;69(1):128-136.

Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma.
König A, Prenzel K, Bogoevski D, Yekebas E, Bubenheim M, Faithova L, Vashist Y, Gawad K, Baldus S, Pantel K, Schneider P, Hölscher A, Izbicki J
ANN SURG ONCOL. 2009;16(2):454-462.

Clinical Relevance of Disseminated Tumor Cells in Bone Marrow and Circulating Tumor Cells in the Blood of Breast Cancer Patients
Müller V, Fehm T, Janni W, Gebauer G, Solomayer E, Pantel K
BREAST CARE. 2009;4(5):333-338.

Cancer micrometastases.
Pantel K, Alix-Panabières C, Riethdorf S
NAT REV CLIN ONCOL. 2009;6(6):339-351.

Pathology: are circulating tumor cells predictive of overall survival?
Pantel K, Riethdorf S
NAT REV CLIN ONCOL. 2009;6(4):190-191.

Detection and Characterization of Disseminated Tumor Cells present in Bone Marrow of Cancer Patients
Riethdorf S, Müller V, Alix-Panabières C, Pantel K
2009. Bone and Cancer. Springer London: 103-117.

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients.
Riethdorf S, Pantel K
BREAST CANCER RES. 2009;11(3):10.

Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?
Scher H, Pantel K
J CLIN ONCOL. 2009;27(10):1531-1533.

Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.
Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell J, Rebillard X, Pantel K
CLIN CANCER RES. 2009;15(3):1032-1038.

Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, Kasimir-Bauer S
BREAST CANCER RES. 2009;11(5):71.

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment.
Slade M J, Payne R, Riethdorf S, Ward B, Zaidi S A, Stebbing J, Palmieri C, Sinnett H, Kulinskaya E, Pitfield T, McCormack R, Pantel K, Coombes R
BRIT J CANCER. 2009;100(1):160-166.

Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion.
Wrage M, Ruosaari S, Eijk P, Kaifi J, Hollmén J, Yekebas E, Izbicki J, Brakenhoff R, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H
CLIN CANCER RES. 2009;15(5):1566-1574.

Circulating tumor cells and bone marrow micrometastasis.
Alix-Panabières C, Riethdorf S, Pantel K
CLIN CANCER RES. 2008;14(16):5013-5021.

Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer.
Dango S, Sienel W, Schreiber M, Stremmel C, Kirschbaum A, Pantel K, Passlick B
LUNG CANCER. 2008;60(3):426-433.

Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
Fehm T, Müller V, Alix-Panabières C, Pantel K
BREAST CANCER RES. 2008;10(1):1.

Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, Pantel K
J CLIN ONCOL. 2008;26(30):4928-4933.

Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.
Müller I, Beeger C, Alix-Panabières C, Rebillard X, Pantel K, Schwarzenbach H
CLIN CHEM. 2008;54(4):688-696.

HER2 as marker for the detection of circulating tumor cells.
Müller V, Pantel K
BREAST CANCER RES TR. 2008.

Detection, clinical relevance and specific biological properties of disseminating tumour cells.
Pantel K, Brakenhoff R, Brandt B
NAT REV CANCER. 2008;8(5):329-340.

Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.
Riethdorf S, Pantel K
PATHOBIOLOGY. 2008;75(2):140-148.

Review: Biological relevance of disseminated tumor cells in cancer patients.
Riethdorf S, Wikman H, Pantel K
INT J CANCER. 2008;123(9):1991-2006.

A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Schrohl A, Müller V, Christensen I, Pantel K, Thomssen C, Bruenner N
TUMOR BIOL. 2008;29(3):181-187.

Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
Schwarzenbach H, Chun F, Müller I, Seidel C, Urban K, Erbersdobler A, Huland H, Pantel K, Friedrich M
BJU INT. 2008;102(2):253-258.

Methods of cancer diagnosis, therapy and prognosis
Schwarzenbach H, Pantel K
2008. Methods of cancer diagnosis, therapy and prognosis. Springer, 481-497.

Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer.
Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E
ANN NY ACAD SCI. 2008;1137:190-196.

Cancer micrometastasis and tumour dormancy.
Wikman H, Vessella R, Pantel K
APMIS. 2008;116(7-8):754-770.

Genome-wide microarray gene expression, array-CGH analysis, and telomerase activity in advanced ovarian endometriosis: a high degree of differentiation rather than malignant potential.
Zafrakas M, Tarlatzis B, Streichert T, Pournaropoulos F, Wölfle U, Smeets S, Wittek B, Grimbizis G, Brakenhoff R, Pantel K, Bontis J, Günes C
INT J MOL MED. 2008;21(3):335-344.

Current status in human breast cancer micrometastasis.
Alix-Panabières C, Müller V, Pantel K
CURR OPIN ONCOL. 2007;19(6):558-563.

Detection and characterization of putative metastatic precursor cells in cancer patients.
Alix-Panabières C, Vendrell J, Pellé O, Rebillard X, Riethdorf S, Müller V, Fabbro M, Pantel K
CLIN CHEM. 2007;53(3):537-539.

Lymph node micrometastases in lung cancer.
Harms-Effenberger K, Sienel W, Pantel K
Cancer Treat Res. 2007;135:167-175.

Short tandem repeat polymorphism in exon 4 of esophageal cancer-related gene 2 detected in genomic DNA is a prognostic marker for esophageal cancer.
Kaifi J, Rawnaq T, Schurr P, Yekebas E, Mann O, Merkert P, Link B, Kalinin V, Pantel K, Sauter G, Strate T, Izbicki J
AM J SURG. 2007;194(3):380-384.

L1 is associated with micrometastatic spread and poor outcome in colorectal cancer.
Kaifi J, Reichelt U, Quaas A, Schurr P, Wachowiak R, Yekebas E, Strate T, Schneider C, Pantel K, Schachner M, Sauter G, Izbicki J
MODERN PATHOL. 2007;20(11):1183-1190.

Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis.
Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, Yekebas E, Schuch G, Izbicki J, Pantel K, Bokemeyer C, Fiedler W
CLIN CANCER RES. 2007;13(1):76-80.

The clinical significance of circulating tumor cells.
Pantel K, Alix-Panabières C
NAT REV CLIN ONCOL. 2007;4(2):62-63.

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.
Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K
CLIN CANCER RES. 2007;13(3):920-928.

Central mesenteric lymph node BER-Ep4+ cells in colorectal cancer: challenge to sentinel node concept?
Schurr P, Behnke S, Kaifi J, Bogoevski D, Link B, Mann O, Strate T, Pantel K, Izbicki J, Yekebas E
DIGEST SURG. 2007;24(1):19-27.

Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
Schwarzenbach H, Chun F, Lange I, Carpenter S, Gottberg M, Erbersdobler A, Friedrich M, Huland H, Pantel K
INT J CANCER. 2007;120(7):1465-1471.

A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
Schwarzenbach H, Müller V, Beeger C, Gottberg M, Stahmann N, Pantel K
BREAST CANCER RES. 2007;9(5):66.

Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer.
Sienel W, Mecklenburg I, Dango S, Ehrhardt P, Kirschbaum A, Passlick B, Pantel K
CLIN CANCER RES. 2007;13(13):3840-3847.

Tumor cell dormancy: an NCI workshop report.
Vessella R, Pantel K, Mohla S
CANCER BIOL THER. 2007;6(9):1496-1504.

Microsatellite analysis in serum DNA as a diagnostic tool for distinction of patients with unknown pancreatic masses.
Wachowiak R, Kaifi J, Schwarzenbach H, Yekebas E, Merkert P, Schurr P, Hansen B, Reichelt U, Strate T, Pantel K, Izbicki J
DIAGN MOL PATHOL. 2007;16(3):174-178.

Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
Wischnewski F, Friese O, Pantel K, Schwarzenbach H
MOL CANCER RES. 2007;5(7):749-759.

The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence
Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K
CANCER-AM CANCER SOC. 2005;103(5):884-91.

Sentinel Lymph Node Dissection and Micrometastasis Detection in Bone Marrow and Lymph Nodes: Molecular Oncology of Breast Cancer
Müller V, Kasimir-Bauer S, Pantel K
2004. Molecular Oncology of Breast Cancer. Ross J, Hortobagyi G (eds.). Jones and Bartlett, 117-127.

Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer
Schwarzenbach H, Müller V, Stahmann N, Pantel K
ANN NY ACAD SCI. 2004;1022:25-32.

Detection and characterisation of occult metastatic cells in bone marrow of breast cancer patients: Micrometastasis
Braun S, Müller V, Pantel K
2003. Micrometastasis. Pantel K (eds.). Kluwer Academic Press, 47-66.

Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells
Hemsen A, Riethdorf L, Brünner N, Berger J, Ebel S, Thomssen C, Jänicke F, Pantel K
INT J CANCER. 2003;107(6):903-9.

Clinical Relevance of Micrometastatic Disease in Patients with Solid Tumors
Muller V, Pantel K
AM J CANCER. 2003;2(2):77-86.

Correlation on serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu determined by immunohistochemistry in primary tumors
Witzel I, Thomssen C, Pantel K, Neumann R, Carney W, Loening T, Jaenicke F, Müller V
BREAST CANCER RES TR. 2003;82, Suppl. 1:S 143.

Letzte Aktualisierung aus dem FIS: 30.10.2024 - 03:14 Uhr